技术新讯 > 有机化学装置的制造及其处理,应用技术 > 以噁二唑为连接链的c3/c3氟喹诺酮二聚体衍生物及其制备方法和应用的制作方法  >  正文

以噁二唑为连接链的c3/c3氟喹诺酮二聚体衍生物及其制备方法和应用的制作方法

  • 国知局
  • 2024-06-20 11:53:46

专利名称::以噁二唑为连接链的c3/c3氟喹诺酮二聚体衍生物及其制备方法和应用的制作方法技术领域::本发明涉及药物化学合成技术领域:,具体涉及以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物及其制备方法和作为制备治疗肿瘤及抗微生物感染疾病的药物的应用。背景技术::氟喹诺酮(FQ)为上世纪80年代以氟哌酸(诺氟沙星)为代表发展而来的临床抗菌药,目前已有近30个品种广泛应用于临床。氟喹诺酮的作用靶点拓扑异构酶(TOPO)与哺乳动物的TOPO具有同源序列相似性,而TOPO也是抗肿瘤药物作用的新靶点,据此把抗菌药FQ转化为抗肿瘤药FQ是目前研究的一个新方向。目前已经设计合成了结构包括二环喹诺酮、三环喹诺酮、四环喹诺酮、手性喹诺酮、类黄酮类等抗肿瘤FQ化合物,但候选化合物均存在毒性与活性相平行或体内溶解度差而导致的生物利用度低或体内易被代谢失活等亟待要解决的共性问题(王晓天等,中国药学杂志,2004,外,890.)。目前已上市的抗菌FQ药物均具有6-氟-7-氮杂环取代-4-酮喹啉或萘啶-3-羧基药效团骨架,且已发现氟喹诺酮的C-3羧基对抗肿瘤活性并非必要,用苯并五元稠杂环取代的化合物(尤启冬等,中国专利,CN1473827A)或其他(稠)杂环取代的化合物(胡国强等,化学学报,2008,66,2157.)具有强的抗肿瘤活性,这表明氟喹诺酮(FQ)骨架对抗肿瘤起关键作用。己有的FQ抗肿瘤化合物均含有一个FQ单元,而一个分子中含有两个FQ结构单元的化合物尚未见报道,另外,1,3,4-噁二唑类化合物虽有大量的合成报道,但以FQ骨架为取代基的研究尚未见报道。发明内容本发明的目的之一是提供一系列以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物;本发明的目的之二是提供一种上述衍生物的制备方法;本发明的目的之三是提供上述衍生物的应用。为了实现以上目的,本发明所采用的技术方案是一种以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其结构通式(I)如下所示:oo(I)其中Rj和R/为任选被独立地选自H、(d-do)烷基、(C3-do)环烷基、(d-do)卤代烷基、取代的芳香烃基或取代的杂环芳香烃基;R2和R2'为任选被独立地选自H、(d-C7)烷基、(CrC7)环烷基、取代的芳香烃基、取代的杂环芳香烃基、烃类酰基或磺酰基;R3和R3'为任选被独立地选自H、(d-Cs)烷基、(C3-C5)环烷基、取代的芳香烃基或取代的杂环芳香烃基;X和Y为任选被独立地选自(a)CH;(b)N;或(c)与卣素、烃基、烃氧基、烃硫基、氨基、取代氨基、取代的芳香烃基或取代的杂环芳香烃基相连的碳原子。Rj和X、R卩和Y可同时或独立地构成五元、六元或七元的饱和或不饱和硫、氧、氮杂环。Rj和R/独立地优选为乙基、环丙基、FCH2CH2-、单氟代苯基或二氟代苯基;R2和R2'独立地优选为H、甲基或乙基;R3和R3'独立地优选为H或甲基;X和Y独立地优选为CH、N、与氟相连的碳原子或与甲氧基相连的碳原子。优选地,R!和X、RV和Y可同时或独立地构成六元饱和硫、氧、氮杂环。所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物的制备方法,包括如下步骤(1)将结构通式(II)的化合物溶于80%的水合肼,回流反应12~24小时,冷却至室温,之后减压蒸馏直到蒸干,剩余物用水、无水乙醇或二者的混合溶剂重结晶,得到结构通式(III)的化合物;(2)结构通式(III)的化合物再与结构通式(IV)的化合物在三氯氧磷中回流反应6~12小时,冷却至室温,减压蒸馏直到蒸干,剩余物用冰水溶解,滤除不溶物,滤液调pH值为9.510.5,收集产生的固体,水洗至中性,干燥,得目标化合物(I)的粗品,将该粗品悬浮于85%乙醇中,调pH值为3.55.0然后加热溶解,静置冷却后析出晶体,即目标化合物(I)的盐,将产生的盐溶于水中,碱化至pH值为9.0~10.0,收集生成的固体,水洗至中性,干燥即得目标化合物(I)的纯品。步骤(2)中结构通式(III)的化合物与结构通式(IV)的化合物反应的摩尔比为1:1。其合成路线如下<formula>formulaseeoriginaldocumentpage12</formula><formula>formulaseeoriginaldocumentpage13</formula>(IV)u)R!和R!'为任选被独立地选自H、(d-do)烷基、(C3-do)环垸基、(d-dQ)卤代烷基、取代的芳香烃基或取代的杂环芳香烃基;R2和R2'为任选被独立地选自H、(d-C7)烷基、(CVC7)环垸基、取代的芳香烃基、取代的杂环芳香烃基、烃类酰基或磺酰基;R3和R3'为任选被独立地选自H、(d-Cs)垸基、(C3-Cs)环垸基、取代的芳香烃基或取代的杂环芳香烃基;X和Y为任选被独立地选自(a)CH;(b)N;或(c)与卤素、烃基、烃氧基、烃硫基、氨基、取代氨基、取代的芳香烃基或取代的杂环芳香烃基相连的碳原子。本发明的氟喹诺酮二聚体衍生物对实验白血病癌细胞株具有强的细胞毒作用,对大肠埃希氏标准菌株具有强的生长抑制活性。其中环丙系列和左氧氟系列化合物的细胞毒活性与对照10-羟基喜树碱的活性相当,部分化合物的活性优于对照。同时,本发明的氟喹诺酮二聚体衍生物对革兰氏大肠埃希氏标准菌株具有强的生长抑制活性,部分化合物的活性优于对照环丙沙星和左氧氟沙星。本发明的化合物具有强的抗肿瘤活性和强的抗革兰氏阴性菌活性,除直接使用外,也可通过与人体可接受的酸,如盐酸、氢溴酸、硫酸、磷酸等无机酸及枸橼酸、马来酸、酒石酸、葡萄糖酸等有机酸成盐,然后与药用载体混合制备成固体剂型或水针剂型作为抗肿瘤药物或抗微生物感染药物。具体实施例方式下面结合实施例对本发明作进一步阐述,但这些实施例不是对本发明的任何限制。实施例1制备l-乙基-6-氟-7-哌嗪-l-基-4(l/i)-喹啉酮-3-甲酰肼(诺氟沙星酰肼1)将诺氟沙星(50g,157mmo1)溶于100mL80。/。的水合肼,回流反应18小时,冷却至室温,减压蒸馏直到蒸干,剩余物用300mL无水乙醇重结晶,得黄色固体1,收率74%。mp186187°C;IR(KBr)v:3456,2897,1648,1567,1527,1473,1255,869cm-1;'HNMR(DMSO-d6)A10.56(brs,1H,CONH),8.86(s,1H,2-H),7.86(d,1H,5-H),7.24(d,1H,8-H),4.53(brs,2H,NH2),4.62(q,2H,NCH2),3.32(t,4H,piperazine-H),2.67(t,4H,piperazine-H),I.36(t,3H,CH3);MS附/z:356(M+Na),334(M+H);Anal,calcdforC16H2。FN502:C57.65,H6.05,N21.01;foundC57.84,H6.15,N21.24。实施例2制备1-乙基-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-甲酰肼(培氟沙星酰肼2)以培氟沙星为原料,按实施例1相同的制备方法可得化合物2,收率68%。mp192194°C;IR(KBr)v:3387,3025,1638,1557,1525,1456,1255,886cm-1;NMR(DMSO-d6)(5:10.46(brs,1H,CONH),8.87(s,1H,2-H),7.82(d,1H,5-H),7.32(d,1H,8-H),4.56(brs,2H,NH2),4.42(q,2H,NCH2),3.35(t,4H,piperazine-H),2.66(t,4H,piperazine-H),2.37(s,3H,N-CH3),1.34(t,3H,CH3);MS附々348(M+H);Anal,calcdforC17H22FN502:C58.78,H6.38,N20.16;foundC58.94,H6.20,N20.40。实施例3制备1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-甲酰肼(环丙沙星酰肼3)以环丙沙星为原料,按实施例1相同的制备方法可得化合物3,收率70%。mp226~227°C;IR(KBr)v:3428,3309,2940,2834,1661,1626,1471cm—1;^NMR(DMSO-d6)S:1.20~1.35(m,4H,环丙國H),3.09~3.12(m,4H,piperazine-H),3.25~3.27(m,4H,piperazine-H),3.45~3.51(m,1H,环丙-H),4.45(brs,2H,NH2),7.32(d,1H,8-H),8.01(d,1H,5-H),8.77(s,1H,2-H),10.83(s,1H,CONH);MSm/z:346(M+H);Anal,calcdforC17H20FN5O2:C59.12,H5.84,N20.28;foundC59.36,H5.67,N20.46。实施例4制备l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)斗(l/Z)-喹啉酮-3-甲酰肼(N-甲基环丙沙星酰肼4)以N-甲基环丙沙星为原料,按实施例1相同的制备方法可得化合物4,收率74%。mp232~234°C;IR(KBr)v:3352,3028,2876,1646,1627,1557,1473cm-1;'HNMR(DMSO-A)<5:1.22~1.36(m,4H,环丙-H),2.34(s,3H,N-CH3),2.76~3.03(m,4H,piperazine-H),3.273.34(m,4H,piperazine-H),3.40~3.54(m,1H,环丙-H),4.46(brs,2H,NH2),7.30(d,1H,8-H),8.02(d,1H,5-H),8.86(s,1H,2-H),10.57(s,1H,CONH);MS360(M+H);Anal,calcdforC18H22FN502:C60.15,H6.17,N19.49;foundC60.32,H6.02,N19.72。实施例5制备1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-甲酰肼(恩诺沙星酰肼5)以恩诺沙星为原料,按实施例1相同的制备方法可得化合物5,收率74%。mp236~238°C;IR(KBr)v:3356,3037,2965,1716,1624,1547,1456,1121cm";&NMR(DMSO-c4)&1.21~1.34(m,7H,CH3和环丙-H),2.27(q,2H,N-CH2),2.71~3.12(m,4H,piperazine-H),3.53~3.47(m,5H,piperazine-H和环丙-H),4.46(brs,2H,NH2),7.35(d,1H,8-H),8.04(d,1H,5-H),8.79(s,1H,2-H),10.85(s,1H,CONH);MSw/z:374(M+H);Anal,calcdforCi9H24FN502:C61.11,H6.48,N18.75;foundC61.30,H6.62,N18.81。实施例6制备(±)-8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-甲酰肼(氧氟沙星酰肼6)将150mmol的氧氟沙星溶于100mL80%的水合肼,回流反应12小时,冷却至室温,减压蒸馏直到蒸干,剩余物用100mL水重结晶,得化合物6,收率80%。mp201202°C;IR(KBr)v:3329,1671,1567,1475cm";'HNMR(DMSO-4)&1.44(《3H,恶嗪环-CH3),2.25(s,3H,N-CH3),2.48(t,4H,pip醒ine-H),3.14~3.27(m,4H,piperazine-H),4.34~4.53(m,2H,恶嗪环-H),4.58(d,2H,NH2),4.85(q,1H,恶嗪环陽H),7.51(d,1H,5-H),8.77(s,1H,2-H),10.62(s,1H,CONH);MS附/z:376(M+H);Anal,calcdforC18H22FN503:C57.59,H5.91,N18.86;foundC57.44,H6.18,N18.72。实施例7制备(S)-1,8-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-甲酰肼(左氧氟沙星酰肼7)以左氧氟沙星为原料,按实施例6相同的制备方法可得化合物7,收率84%。mp207~208;IR(KBr)v:3345,2864,1674,1468cm";^-NMR(DMS0-4)&1.46(d,3H,恶嗪环-CH3),2.23(s,3H,N-CH3),2.54~3.32(m,8H,piperazine-H),4.40~4.86(m,3H,恶嗪环-H),7.54(d,1H,5-H),8.82(s,1H,2-H),10.60(s,1H,CONH);MS附/z:376(M+H);Anal,calcdforC19H24FN502:C57.59,H5.91,N18.86;foundC57.78,H6.04,N18.68。实施例8制备1,8-[l,2-(乙硫基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//>喹啉酮-3-甲酰肼(芦氟沙星酰肼8)以芦氟沙星为原料,按实施例6相同的制备方法可得化合物8,收率72%。mp236~238;IR(KBr)v:3362,3047,2868,1642,1468cm";^墨NMR(DMSO-^4)&2.44(s,3H,CH3),2.68-3.56(m,10H,噻嗪环-SCH2和哌嗪-H),4.53(brs,2H,NH2),4.70(t,2H,噻嗪环-NCH2),7.67(d,1H,5-H),8.86(s,1H,2-H),10.63(s,1H,CONH);MS附/z:378(M+H);Anal,calcdforC17H20FN5O2S:C54.10,H5.34,N18.55;foundC54.28,H5.17,N18.72。实施例9制备l-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-l-基)-4-(l^)-喹啉酮-3-甲酰肼(氟罗沙星酰肼9)以氟罗沙星为原料,按实施例6相同的制备方法可得化合物9,收率80%。mp236~238;IR(KBr)v:3354,3027,2965,1647,1468,1227cm";'H-NMR(DMSO-4)&2.34(s,3H,CH3),2.64(t,4H,哌嗪-H),3.35(t,4H,哌嗪-H),4.47(t,2H,NCH2),4.56(brs,2H,NH2),4.84(t,2H,FCH2),7.82(d,1H,5-H),8.89(s,1H,2-H),10.57(s,1H,CONH);MSm/z:384(M+H);Anal,calcdforC17H20F3N5O2:C53.26,H5.26,N18.27;foundC53.42,H5.08,N18.52。实施例10制备l-乙基-6,8-二氟-7-(3-甲基哌嗪-l-基)-4-(l印-喹啉酮-3-甲酰肼(洛美沙星酰肼10)以洛美沙星为原料,按实施例6相同的制备方法可得化合物10,收率58%。mp212~214;IR(KBr)v:3347,3006,2934,1627,1456,1280cm-1;!H-NMR(DMSO-d6)&1.33(d,3H,CH3),1.42(t,3H,CH3),3.16~3.38(m,7H,piperazine-H),4.47~4.58(m,4H,,2禾口NCH2),7.84(d,1H,5-H),9.02(s,1H,2-H),10.52(s,1H,CONH);MSw/z:366(M+H);Anal.calcdforC17H21F2N502:C55.88,H5.79,N19.17;foundC59.02,H5.64,N19.42。实施例11制备1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-甲酰肼(依诺沙星酰肼11)将100mmol的依诺沙星溶于60mL80%的水合肼,回流反应24小时,冷却至室温,减压蒸馏直到蒸干,剩余物用200mL质量百分比浓度为50M的乙醇水溶液重结晶,得化合物ll,收率56%。mp225227;IR(KBr)v:3328,3026,2936,1629,1473,1268cm";!H-NMR(DMSO-c4)&1.38(t,3H,CH3),2.873.35(m,8H,piperazine-H),4.47~4.64(m,4H,NH2禾口NCH2),7.86(d,1H,5-H),9.17(s,1H,2-H),10.64(s,1H,CONH);MSw/z:335(M+H);Anal,calcdforC15H19F2N602:C53.88,H5.73,N25.13;foundC53.67,H5.56,N25.32。实施例12制备1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-甲酰肼(加替沙星酰肼12)以加替沙星为原料,按实施例11相同的制备方法可得化合物12,收率65%。mp187~189;IR(KBr)v:3346,3018,2897,1626,1543,1272cm";'H-NMR(DMSO陽^)&1.26~1.35(m,7H,环丙-H和CH3),2.67~3.32(m,7H,piperazine-H),3.51~3.62(m,1H,环丙-H),3,87(s,3H,OCH3),4.45(brs,2H,NH2),7.78(d,1H,5-H),9.04(s,1H,2-H),10.66(s,1H,CONH);MS附/z:390(M+H);Anal,calcdforC19H24FN503:C58.60,H6.21,N17.98;foundC58.81,H6.05,N18.12。实施例13制备1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-甲酰肼(二氟沙星酰肼13)以二氟沙星为原料,按实施例11相同的制备方法可得化合物13,收率72%。mp254~256;IR(KBr)v:3357,3027,3006,2925,1624,1557,1478,1276cm";^-NMR(DMSO-4)&2.26(s,3H,CH3),3.03~3.38(m,8H,哌嗪-H),4.52(brs,2H,NH2),7.64~7.86(m,6H,5-H,8-HandPh-H),9.14(s,1H,2-H),10.62(s,1H,CONH);MSm/z:414(M+H);Anal,calcdforC21H2IF2N502:C61.01,H5.12,N16.94;foundC61.24,H5.25,N17.13。实施例14制备l-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-甲酰肼(替马沙星酰肼14)以替马沙星为原料,按实施例11相同的制备方法可得化合物14,收率76%。mp258~260;IR(KBr)v:3364,3038,3016,2947,1638,1564,1462,1278cm-1;^-NMR(固SO-^)<5:1.34(d,3H,CH3),2.64~3.35(m,7H,piperazine-H),4.56(brs,2H,NH2),7.72~7.85(m,5H,5-H,8-HandPh隱H),9.16(s,1H,2隱H),10.65(s,1H,CONH);MS附/z:432(M+H);Anal,calcdforC21H20F3N5O2:C58.47,H4.67,N16.23;foundC58.64,H4.50,N16.45。实施例15制备2,5-双[1-乙基-6-氟-7-哌嗪-1-基-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(15)诺氟沙星酰肼l(2.0g,6.0mmol)与等摩尔的诺氟沙星(6.0mmol)在50mL三氯氧磷中回流12小时,冷却至室温,减压蒸馏直到蒸干,剩余物用200mL冰水溶解,滤除不溶物,滤液用30%的氢氧化钠水溶液调pH为10,收集产生的固体,水洗至中性,干燥,得粗品,将该粗品悬浮于50mL85。/。的乙醇中,用浓盐酸调pH值为3.5,然后加热溶解,静置冷却析出晶体,即得化合物15的盐酸盐,将产生的盐酸盐溶于去离子水中,用浓氨水碱化至pH为9.5,收集产生的固体,水洗至中性,干燥得黄色分析纯游离碱15,收率45%。mp212~214°C;IR(KBr)v:3342,3016,3016,2876,1624,1556,1446,1257cm";化NMR(DMS0-4)&1.36(t,6H,2xCH3),2.68~3.17(m,16H,2x哌嗪-H),4.36(brs,4H,2xN-CH2),7.36(d,2H,2x8-H),7.78(d,2H,2x5-H),8.84(s,2H,2x2隱H);MS/w/z:617(M+H);Anal,calcdforC32H34F2N803:C62.33,H5.56,N18.17;foundC62.51,H5.42,N18.41。实施例16制备2-[l-乙基-6-氟-7-哌嗪-l-基-4(m)-喹啉酮-3-基]-5-[l-乙基-6-氟-7-(4-甲基哌嗪)-1-基-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(16)以诺氟沙星酰肼l(2.0g,6.0mmol)或培氟沙星酰肼2(2.1g,6.0mmol)与等摩尔的培氟沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物16,收率38%。mp203204。C;IR(KBr)v:3346,3028,3007,2936,1622,1556,1456,1263cm-1;^-NMR(DMSO-^)&1.34~1.42(m,6H,2xCH3),2.36(s,3H,N-CH3),2.62~3.34(m,16H,2x哌嗪-H),4.354.46(m,4H,2xCH2),7.42(d,2H,2x8-H),7.86(d,2H,2x5-H),8.89(s,2H,2x2-H);MS附/z:631(M+H);Anal,calcdforC33H36F2N803:C62.85,H5.75,N17.77;foundC63.07,H5.42,N17.92。实施例17制备2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-(1-环丙基-6-氟-7-哌嗪-1-基-4-(1/0-喹啉酮_3-基)-1,3,4-噁二唑(17)诺氟沙星酰肼l(2.0g,6.0mmoD或环丙沙星酰肼3(2.0g,6.0mmol)与等摩尔的环丙沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物17,收率42%。mp217219。C;IR(KBr)v:3328,2947,1626,1553,1472,1258,886cm—1;'H-NMR(DMSO-c4)<5:1.241.43(m,7H,环丙-H和CH3),2.54~3.28(m,16H,2x哌嗪陽H),3.65(m,1H,环丙-H),4.50(q,2H,NCH2),7.74(d,2H,2x8-H),8.25(d,2H,2x5-H),9.04(s,2H,2x2-H);MS附/z:629(M+H);Anal,calcdforC33H34F2N803:C63.05,H5.45,N17.82;foundC63.26,H5.37,N17.78。实施例18制备2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[1-环丙基-6-氟-7-(4-甲基哌嗪_1_基)_4_(1印-喹啉酮_3-基]-1,3,4-噁二唑(18)诺氟沙星酰肼l(2.0g,6.0mmol)或N-甲基环丙沙星酰肼4(2.2g,6.0mmoD与等摩尔的N-甲基环丙沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物18,收率46%。mp210212。C;IR(KBr)v:3346,2927,1618,1565,1478,1263,874cm—1;!H-NMR(DMSO-A)&1.22~1.46(m,7H,环丙-H和CH3),2.38(s,3H,N-CH3),2.603.37(m,16H,2x哌嗪-H),3.72(m,1H,环丙-H),4.54(q,2H,NCH2),7.82(d,2H,2x8陽H),8.18(d,2H,2x5國H),9.06(s,2H,2x2-H);MSw/z:643(M+H);Anal,calcdforC34H36F2N803:C63.54,H5.65,N17.43;foundC63.68,H5.44,N17.55。实施例19制备(±)-2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-{8,l-[l,2-(氧丙基)-6-氟-7-(4-乙基哌嗪-1-基)-4-(1印-喹啉酮-3-基]-1,3,4-噁二唑(19)诺氟沙星酰肼l(2.0g,6.0mmo1)或氧氟沙星酰肼6(2.3g,6.0mmo1)与等摩尔的氧氟沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物20,收率24%。mp226~228。C;IR(KBr)v:3268,3036,1634,1586,1573,1257,796cm-1;力-NMR(DMSO-c4)A1.32~1.46(m,6H,2xCH3),2.28(s,3H,N-CH3),2.53~3.36(m,16H,2x哌嗪-H),4.46~4.57(m,4H,NCH2和OCH2),4.82(m,1H,NCH),7.46(d,1H,8-H),7.67,7.76(d,2H,2x5-H),9.03,9.14(s,2H,2x2-H);MS附/z:659(M+H);Anal,calcdforC35H36F2N804:C62.00,H5.51,N17.01;foundC62.22,H5.43,N17.18。实施例20制备(S)-2-(l-乙基-6-氟-7-哌嗪-l-基-4-(l/Z)-喹啉酮-3-基)-5-(8,l-[l,2-(氧丙基)-6-氟_7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(20)诺氟沙星酰肼l(2.0g,6.0mmo1)或左氧氟沙星酰肼7(2.3g,6.0mmo1)与等摩尔的左氧氟沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物20,收率16%。mp210210。C;IR(KBr)v:3257,3028,1625,1577,1562,1286,814cm-1;'H-顧R(DMS0隱c4)(5:1.36~1.48(m,6H,2xCH3),2.26(s,3H,N-CH3),2.57~3.35(m,16H,2x哌嗪-H),4.50~4.57(m,4H,NCH2和OCH2),4.87(m,1H,NCH),7.42(d,1H,8陽H),7.35,7.56(d,2H,2x5-H),8.87,9.15(s,2H,2x2-H);MS附/z:659(M+H);Anal,calcdforC34H36F2N804:C62.00,H5.51,N17.01;foundC62.18,H5.64,N17.24。实施例21制备2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[8,l-(硫乙基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1/0-喹啉酮-3-基]-1,3,4-噁二唑(21)诺氟沙星酰肼l(2.0g,6.0mmoD或芦氟沙星酰肼8(2.3g,6.0mmoD与等摩尔的芦氟沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物21,收率37%。mp243~245。C;IR(KBr)v:3246,2976,1638,1584,1576,1267,863cm";'H-NMR(DMSO-^4)&1.32(t,3H,CH3),2.27,2.30(s,6H,2xN-CH3),2.66~3.74(m,18H,2x哌嗪陽H和SCH2),4.50~4.84(m,4H,2xNCH2),7.36(d,1H,8-H),7.46,7.68(d,2H,2x5-H),8.94,9.18(s,2H,2x2-H);MS附/z:661(M+H);Anal,calcdforC33H34F2N803S:C59.99,H5.19,N16.96;foundC60.21,H5.02,N17.13。实施例22制备2-(l-乙基-6-氟-7-哌嗪-l-基-4-(1//)-喹啉酮-3-基)-5-[1-(2-氟乙基)-6,8-二氟-7國(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(22)诺氟沙星酰肼l(2.0g,6.0mmo1)或氟罗沙星酰肼9(2.3g,6.0mmo1)与等摩尔的氟罗沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物22,收率42%。mp238240。C;IR(KBr)v:3246,3036,16341584,1557,1455,1274,775cm";^-NMR(DMSO-^)&1.36(t,3H,CH3),2.26(s,3H,N-CH3),2.45~3.34(m,16H,2x哌嗪-H),4.62~5.02(m,6H,2xNCH2和FCH2),7.26(d,1H,8-H),7.68,7.84(d,2H,2x5-H),8.86,9.06(s,2H,2x2-H);MS附/z:661(M+H);Anal,calcdforC33H34F4N803:C59.45,H5.14,N16.81;foundC59.32,H5.32,N16.97。实施例23制备2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(23)诺氟沙星酰肼1(2.0g,6.0mmol)或洛美沙星酰肼10(2.2g,6.0mmol)与等摩尔的洛美沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物23,收率17%。mp212214。C;IR(KBr)v:3317,3028,16261576,1564,1457,1268,824cm-1;'H隱NMR(DMSO-^)&1.34~1.52(m,9H,3xCH3),2.62~3.36(m,15H,2x哌嗪-H),4.674.74(m,4H,2xNCH2),7.36(d,1H,8-H),7.86,7.88(d,2H,2x5-H),8.92,9.08(s,2H,2x2-H);MSm/z:649(M+H);Anal,calcdforC33H35F3N803:C61.10,H5.44,N17.27;foundC61.26,H5.28,N17.45。实施例24制备2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6-氟-7-哌嗪-1-基_4_(1//)_萘啶酮-3-基]_1,3,4-噁二唑(24)诺氟沙星酰肼1(2.0g,6.0mmol)或依诺沙星酰肼11(2.0g,6.0mmol)与等摩尔的依诺沙星或诺氟沙星为原料,按实施例15相同的制备方法可得化合物24,收率20%。mp227229。C;IR(KBr)化3324,3008,2879,1624,1557,1468,1274,843cm";^-NMR(DMSO-A)1.351.46(m,6H,2xCH3),2.423.17(m,16H,2x哌嗪-H),4.62~4.84(m,4H,2xNCH2),7.54(d,1H,8-H),7.82,8.23(d,2H,2x5-H),8.96,9.21(s,2H,2x2-H);MS附/z:618(M+H);Anal,calcdforC31H33F2N903:C60.28,H5.39,N20.41;foundC60.44,H5.13,N20.60。实施例25制备2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(25)诺氟沙星酰肼1(2.0g,6.0mmol)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星(Gatifloxacin)或诺氟沙星为原料,按实施例15相同的制备方法可得化合物25,收率14%。mpl87189。C;IR(KBr)v:3362,3017,2884,1636,1567,1568,1257,864cm";!H-NMR(DMSO-^)&1.18~1.42(m,10H,环丙-H和2xCH3),2.46~3.32(m,15H,2x哌嗪-H),3.64(m,1H,环丙-H),3.84(s,3H,OCH3),4.67(q,2H,NCH2),7.32(d,1H,8-H),7.78,8.14(d,2H,2x5-H),8.87,9.06(s,2H,2x2-H);MS附/z:673(M+H);Anal,calcdforC35H38F2N804:C62.49,H5.69,N16.66;foundC62.72,H5.48,N16.86。实施例26制备2-[l-乙基-6-氟-7-哌嗪-l-基-4-(1//)-喹啉酮-3-基]-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪_1_基)-4-(17^-喹啉酮-3-基]-1,3,4-噁二唑(26)诺氟沙星酰肼1(2.0g,6.0mmol)或二氟沙星酰肼13(2.5g,6.0mmol)与等摩尔的二氟沙星(Difloxacin)或诺氟沙星为原料,按实施例15相同的制备方法可得化合物26,收率36%。mp24024rC;IR(KBr)v:3268,3006,2947,1618,1546,1248,826cm";!H-NMR&1.34(t,3H,CH3),2.26(s,3H,N-CH3),2.47~3.36(m,16H,2x哌嗪-H),4.65(q,2H,NCH2),7.43~7.87(m,8H,2x8-H,2x5-HandPh-H),8.86,9.02(s,2H,2x2-H);MSm/z:697(M+H);Anal,calcdforC37H35F3N804:C63.78,H5.06,N16.08;foundC63.91,H5.22,N16.24。实施例27制备2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二哇(27)诺氟沙星酰肼l(2.0g,6.0mmoD或替马沙星酰肼14(2.6g,6.0mmoD与等摩尔的替马沙星(Temafloxacin)或诺氟沙星为原料,按实施例15相同的制备方法可得化合物27,收率27%。mp246248。C;IR(KBr)v:3258,2956,1623,1567,1238,817cm-1;!關MR3:1.32~1.45(m,6H,2xCH3),2.67~3.28(m,15H,2x哌嗪-H),4.67(q,2H,NCH2),7.38~7.86(m,7H,2x8-H,2x5-HandPh-H),8.88,9.07(s,2H,2x2-H);MS附/z:715(M+H);Anal,calcdforC37H34F4N803:C62.18,H4.79,N15.68;foundC62.33,H4.62,N15.87。实施例28制备2,5-双[l-环丙基-6-氟-7-哌嗪-l-基-4-(l^-喹啉酮-3-基]-l,3,4-噁二唑(28)环丙沙星酰肼3(2.0g,6.0mmo1)与等摩尔的环丙沙星(Ciprofloxacin)为原料,按实施例15相同的制备方法可得化合物28,收率32%。mp235236°C;IR(KBr)v:3345,3038,2946,1627,1579,1227,884cm—1;'H-NMR^1.22~1.34(m,8H,环丙-H),2.76~3.12(m,16H,2x哌嗪-H),3.42(m,2H,2x环丙-H),7.36(d,2H,2x8-H),7.84(d,2H,2x5-H),8.87(s:2H,2x2-H);MS附/z:641(M+H);Anal,calcdforC34H34F2N803:C63.74,H5.35,N17.49;foundC63.88,H5.14,N17.62。实施例29制备2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(l^)-喹啉酮-3-基]-5-[l-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(29)以环丙沙星酰肼3(2.0g,6.0mmol)或N-甲基环丙沙星酰肼4(2.2g,6.0mmol)与等摩尔的N-甲基环丙沙星或环丙沙星为原料,按实施例15相同的制备方法可得化合物29,收率27%。mp224226。C;IR(KBr)v:3327,3028,2856,1622,1547,1238,864cm";!H隱NMRA1.22~1.36(m,8H,环丙-H),2.27(s,3H,N-CH3),2.68-3.26(m,16H,2x哌嗪陽H),3.45(m,2H,2x环丙-H),7.28(d,2H,2x8-H),7.74(d,2H,2x5陽H),8.89(s,2H,2x2隱H);MSw/z:655(M+H);Anal,calcdforC35H36F2N803:C64.21,H5.54,N17,11;foundC64.36,H5.33,N17.36。实施例30制备2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(30)以恩诺沙星酰肼5(2.2g,6.0mmoD或环丙沙星酰肼3(2.0g,6.0mmo1)或与等摩尔的环丙沙星或恩诺沙星为原料,按实施例15相同的制备方法可得化合物30,收率34%。mp218220。C;IR(KBr)v:3317,2952,1624,1556,1247,786cm";'H隱NMR^1.22~1.46(m,11H,2x环丙-H和CH3),2.24(s,3H,N-CH2),2.64~3.21(m,16H,2x哌嗪-H),3.38(m,2H,2x环丙-H),7.32(d,2H,2x8墨H),7.76(d,2H,2x5-H),8.88(s,2H,2x2-H);MS;w/z:669(M+H);Anal,calcdforC36H38F2N803:C64.66,H5.73,N16.76;foundC64.84,H5.57,N16.92。实施例31制备2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(31)以环丙沙星酰肼3(2.0g,6.0mmol)或培氟沙星酰肼2(2.1g,6.0mmol)与等摩尔的培氟沙星或环丙沙星为原料,按实施例15相同的制备方法可得化合物31,收率30%。mp206208。C;IR(KBr)v:3276,2884,1636,1472,1236,788cm—1;^-NMR^1.20~1.42(m,7H,环丙-H和CH3),2.26(s,3H,N-CH2),2.66~3.27(m,16H,2x哌嗪隱H),3.42(m,1H,环丙隱H),4.62(q,2H,NCH2),7.36,7.42(d,2H,2x8-H),7.76(m,2H,2x5-H),8.88~9.03(m,2H:2x2-H);MS附々643(M+H);Anal,calcdforC34H36F2N803:C63.54,H5.65,N17.43;foundC63.73,H5.46,N17.66。实施例32制备(±)-2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-{8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基}-1,3,4-噁二唑(32)以环丙沙星酰肼3(2.0g,6.0mmol)或氧氟沙星酰肼6(2.3g,6.0mmo1)与等摩尔的氧氟沙星或环丙沙星为原料,按实施例15相同的制备方法可得化合物32,收率24%。mp218220。C;IR(KBr)v:3328,3026,2932,1630,1476,1264,787cm";!H國NMRA1.20~1.47(m,7H,环丙隱H禾卩CH3),2.25(s,3H,N-CH3),2.583.17(m,16H,2x哌嗪-H),3.44(m,1H,环丙-H),4.42~4.56(m,2H,OCH2),4.74(m,1H,NCH),7.35(d,1H,8-H),7.56,7.76(d,2H,2x5陽H),9.00(m,2H,2x2-H);MS附/z:671(M+H);Anal,calcdforC35H36F2N804:C62.68,H5.41,N16.71;foundC62.88,H5.27,N17.84。实施例33制备(S)-2-[l-环丙基-6-氟-7-哌嗪-l-基-4(17/)-喹啉酮-3-基]-5-(8,l-[l,2-(氧丙基)]-6-氟_7-(4-甲基哌嗪-1-基)-4(1均-喹啉酮-3-基}-1,3,4-噁二唑(33)以环丙沙星酰肼3(2.0g,6.0mmo1)或左氧氟沙星酰肼7(2.3g,6.0mmo1)与等摩尔的左氧氟沙星或环丙沙星为原料,按实施例15相同的制备方法可得化合物33,收率18%。mp211~212°C;IR(KBr)v:3328,3017,2935,1626,1475,1257,787cm";!H-NMR&1.20~1.45(m,7H,环丙-H和CH3),2.25(s,3H,N-CH3),2.58~3.30(m,16H,2x哌嗪隱H),3.46(m,1H,环丙-H),4.42~4.56(m,2H,OCH2),4.77(m,1H,NCH),7.42(d,1H,8-H),7.53,7.76(d,2H,2x5-H),9.00(br,2H,2x2-H);MS附/z:671(M+H);Anal,calcdforC35H36F2N804:C62.68,H5.41,N16.71;foundC62.80,H5.56,N17.82。实施例34制备2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(l/f)-喹啉酮-3-基]-5-[8,1-(硫乙基)-6-氟-7-(4-甲基哌嗪-l-基)-4-(l印-喹啉酮-3-基]-l,3,4-噁二唑(34)以环丙沙星酰肼3(2.0g,6.0mmol)或芦氟沙星酰肼8(2.3g,6.0mmo1)与等摩尔的芦氟沙星或环丙沙星为原料,按实施例15相同的制备方法可得化合物34,收率45%。mp234236。C;IR(KBr)v:3286,2887,1622,1485,1253,837cm-1;iH-NMR^1.201.36(m,4H,环丙-H),2.27(s,3H,N-CH3),2.56~3.22(m,16H,2x哌嗪-H),3.45~3.56(m,3H,环丙-HandSCH2),4.47(t,2H,NCH2),7.45(d,1H,8-H),7.56,7.82(d,2H,2x5-H),8.87,9.04(d,2H,2x2-H);MS附/z:673(M+H);Anal,calcdforC34H34F2N803S:C60.70,H5.09,N16.66;foundC60.89,H5.17,N16.84。实施例35制备2-[卜环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(2-氟乙基)-6,8-二氟_7_(4-甲基哌嗪_1_基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(35)以环丙沙星酰肼3(2.0g,6.0mmol)或氟罗沙星酰肼9(2.3g,6.0mmoD与等摩尔的氟罗沙星(Fleroxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物35,收率42%。mp248250。C;IR(KBr)v:3237,2865,1637,1476,1243,767cm";^-NMRA1.22~1.33(m,4H,环丙-H),2.26(s,3H,N-CH3),2.50~3.32(m,16H,2x哌嗪隱H),3.45~3.57(m,1H,环丙-H),4.52(t,2H,NCH2),4.82(t,2H,FCH2),7.52(d,1H,8-H),7.64,7.76(m,2H,2x5陽H),8.86,9.07(d,2H,2x2-H);MS/n/z:679(M+H);Anal,calcdforC34H34F4N803:C60.17,H5.05,N16.51;foundC60.37,H5.15,N16.74。实施例36制备2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(177)-喹啉酮-3-基]-5-[l-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(36)以环丙沙星酰肼3(2.0g,6.0mmol)或洛美沙星酰肼10(2.3g,6.0mmol)与等摩尔的洛美沙星(Lomefloxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物36,收率27%。mp212214。C;IR(KBr)v:3246,3027,1624,1557,1268,786cm";'H隱NMR^1.23-1.47(m,10H,环丙-H和2xCH3),2.52~3.28(m,15H,2x哌嗪-H),3.42~3.56(m,1H,环丙-H),4.52,4.67(t,2H,2xNCH2),7.38(d,1H,8-H),7.55,7.80(m,2H,2x5-H),8.88,8.96(d,2H,2x2-H);MS附/z:661(M+H);Anal,calcdforC34H35F4N803:C61.81,H5.34,N16.96;foundC62.13,H5.22,N17.15。实施例37制备2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基)-1,3,4-噁二唑(37)以环丙沙星酰肼3(2.0g,6.0mmo1)或依诺沙星酰肼11(2.0g,6.0mmo1)与等摩尔的依诺沙星(Enoxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物37,收率24%。mp228230。C;IR(KBr)v:3356,3056,1624,1548,1247,885cm.1;iH-NMR&1.23~1.52(m,7H,环丙-H和CH3),2.383.16(m,16H,2x哌嗪-H),3.45~3.67(m,1H,环丙-H),4.85(q,2H,NCH2),7.44(d,1H,8-H),7.62,7.84(m,2H,2x5-H),8.86,9.18(d,2H,2x2陽H);MS附/z:630(M+H);Anal,calcdforC32H33F2N903:C61.04,H5.28,N20.02;foundC61.26,H5.38,N20.27。实施例38制备2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基)-1,3,4-噁二唑(38)以环丙沙星酰肼3(2.0g,6.0mmol)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星(Gatifloxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物38,收率17%。mpl86188。C;IR(KBr)v:3345,3047,1638,1476,1227,847cm—1;!H隱NMR^1.23~1.46(m,10H,环丙-H和2xCH3),2.66~3.25(m,15H,2x哌嗪-H),3.50~3.64(m,2H,2x环丙-H),3.88(s,3H,OCH3),7.42(d,1H,8-H),7.57,7.68(m,2H,2x5陽H),8.76,8.87(d,2H,2x2國H);MS附/z:685(M+H);Anal,calcdforC36H38F2N804:C63.15,H5.59,N16.36;foundC63.40,H5.38,N16.48。实施例39制备2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(l印-喹啉酮-3-基]-5-[l-(4-氟苯基)-6-氟-7-(4-甲基哌嗪小基)-4-(l^)-喹啉酮-3-基)-l,3,4-噁二唑(39)以环丙沙星酰肼3(2.0g,6.0mmol)或二氟沙星酰肼13(2.5g,6.0mmol)与等摩尔的二氟沙星(oxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物39,收率37%。mp238240。C;IR(KBr)v:3342,2876,1628,1548,1247,857cm";'H-NMR&1.20~1.32(m,4H,环丙-H),2.32(s,3H,NCH3),2.60~3.24(m,16H,2x哌嗪-H),3.62(m,1H,环丙-H),7.45~7,74(m,8H,2x8-H,2x5-HandPh-H),8.64,8.82(d,2H,2x2-H);MSw/z:709(M+H);Anal,calcdforC38H35F3N803:C64.40,H4.98,N15.81;foundC64.62,H5.12,N15.70。实施例40制备2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基)-1,3,4-噁二唑(40)以环丙沙星酰肼3(2.0g,6.0mmol)或替马沙星酰肼14(2.6g,6.0mmo1)与等摩尔的替马沙星(Temafloxacin)或环丙沙星为原料,按实施例15相同的制备方法可得化合物40,收率52%。mp257259。C;IR(KBr)v:3268,2945,1632,1558,1254,887cm";'H陽NMRJ:1.20~1.47(m,7H,环丙-H和CH3),2.62~3.38(m,15H,2x哌嗪陽H),3.57(m,1H,环丙-H),7.40~7.84(m,7H,2x8-H,2x5腳HandPh隱H),8.66,8.87(d,2H,2x2-H);MS附/z:727(M+H);Anal,calcdforC38H34F4N803:C62.80,H4.72,N15.42;foundC62.97,H5.32,N15.63。实施例41制备2,5-双[l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二哇(41)N-甲基环丙沙星酰肼4(2.0g,5.6mmol)与等摩尔的N-甲基环丙沙星(5.6mmol)在50mL三氯氧磷中回流6小时,冷却至室温,减压蒸馏直到蒸干,剩余物用200mL冰水溶解,滤除不溶物,滤液用30。/。的氢氧化钠水溶液调pH为9.5,收集产生的固体,水洗至中性,干燥,得粗品,将该粗品悬浮于50mL85y。的乙醇中,用浓盐酸调pH值为4.5,然后加热溶解,静置冷却析出晶体,即得化合物41的盐酸盐,将产生的盐酸盐溶于去离子水中,用浓氨水碱化至pH为9.0,收集产生的固体,水洗至中性,干燥得黄色分析纯游离碱41,收率40%。mp226228。C;IR(KBr)v:3227,3005,2880,1635,1617,1556,1468cm-1;雇R(DMS0-d6)&1.20~1.34(m,8H,2x环丙-H),2.32(s,3H,2xN-CH3),2.64~3.35(m,16H,2xpiperazine-H),3.67(m,2H,2x环丙-H),7.34(brs,2H,2x8-H),7.78(d,2H,2x5陽H),8.87(s,2H,2x2國H);MS附/z:669(M+H);Anal,calcdforC38H38F2N803:C64.66,H5.73,N16.76;foundC64.82,H5.64,N16.85。实施例42制备2-(1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基)-5-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(42)以N-甲基环丙沙星酰肼4(2.0g,5.6mmo1)或恩诺沙星酰肼5(2.1g,5.6mmo1)与等摩尔的恩诺沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物42,收率46%。mp217~218°C;IR(KBr)v:3242,2954,1626,1582,1457,852cm-1;(DMSO-d6)&1.18~1.44(m,11H,2x环丙-H和CH3),2.24-2.35(m,5H,N-CH3和N-CH2),2.66~3.32(m,16H,2xpiperazine-H),3.68(m,2H,2x环丙-H),7.46(brs,2H,2x8-H),7.76(d,2H,2x5-H),8.89(s,2H,2x2邻;MSw/z:682(M+H);Anal,calcdforC39H40F2N8O3:C65.09,H5.91,N16.41;foundC65.27,H5.80,N16.68。实施例43制备(±)-2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(43)以N-甲基环丙沙星酰肼4(2.0g,5.6mrno1)或氧氟沙星酰肼6(2.1g,5.6mmo1)与等摩尔的氧氟沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物43,收率30%。mp228230。C;IR(KBr)v:3257,2867,1624,1557,1476,1267,755cm.1;&NMR(DMSO-d6)&1.21~1.46(m,4H,环丙國H和CH3),2.24~2.36(m,6H,N-CH3和N-CH2),2.58~3.35(m,15H,2xpiperazine隱H),3.72(m,1H,环丙-H),4.54~4.87(m,2H,OCH2),4.92(m,1H,NCH),7.36(d,1H,8-H),7.67,7.68(d,2H,2x5-H),9.04,9.12(s,2H,2x2-H);MSw/z:685(M+H);Anal,calcdforC36H38F2N804:C63.15,H5.59,N16.36;foundC63.38,H5.41,N16.62。实施例44制备(3)-2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(44)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或左氧氟沙星酰肼7(2.1g,5.6mmol)与等摩尔的氧氟沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物44,收率22%。mp211212。C;IR(KBr)v:3246,2886,1624,1567,1454,1248,768cm";NMR(DMSO-d6)&1.21~1.44(m,7H,环丙陽H和CH3),2.23~2.35(m,6H,N-CH3禾口N-CH3),2.55~3.32(m,15H,2xpiperazine-H),3.68(m,1H,环丙-H),4.55~4.87(m,2H,OCH2),4.87(m,1H,NCH),7.34(d,1H,8-H),7.67,7.74(d,2H,2x5-H),9.02,9.15(s,2H,2x2陽H);MS附/z:685(M+H);Anal,calcdforC36H38F2N804:C63.15,H5.59,N16.36;foundC63.36,H5.47,N16.58。实施例45制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1印-喹啉酮-3-基]-5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(45)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或戸氟沙星酰肼8(2.1g,5.6mmoD与等摩尔的芦氟沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物45,收率42%。mp241242。C;IR(KBr)v:3254,2928,1623,1585,1562,1238,778cm.1;!HNMR(DMSO-d6)(5:1.21~1.32(m,4H,环丙隱H),2.23~2.32(m,6H,N-CH3),2.55~3.32(m,16H,2xpiperazine-H),3.55~3.68(m,3H,环丙-H和SCH2),4.70(t,2H,NCH2),7.46(d,1H,8-H),7.58,7.72(d,2H,2x5-H),8.87,9.04(s,2H,2x2-H);MS附/z:687(M+H);Anal,calcdforC35H36F2N803S:C61.21,H5.28,N16.32;foundC61.44,H5.03,N16.50。实施例46制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-l-基)-4-(l^)-喹啉酮-3-基]-l,3,4-噁二唑(46)以N-甲基环丙沙星酰肼4(2.0g,5.6mrno1)或氟罗沙星酰肼9(2.2g,5.6mrno1)与等摩尔的罗氟沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物46,收率38%。mp246248。C;IR(KBr)v:3265,3027,2856,1627,1562,1476,1256,852cm";力NMR(DMSO國d6)&1.20~1.35(m,4H,环丙隱H),2.26~2.37(m,6H,N-CH3),2.62~3.35(m,16H,2xpiperazine-H),3.72(m,1H,环丙-H),4.78(t,2H,NCH2),4.88(t,2H,FCH2),7.44(d,1H,8隱H),7.62,7.84(d,2H,2x5-H),8.89,9.12(s,2H,2x2-H);MS附/z:693(M+H);Anal,calcdforC35H36F4N803:C60.69,H5.24,N16.18;foundC60.86,H5.14,N16.38。实施例47制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(47)以N-甲基环丙沙星酰肼4(2.0g,5.6mrno1)或洛美沙星酰肼10(2.2g,5.6mmo1)与等摩尔的洛美沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物47,收率25%。mp217218。C;IR(KBr)v:3327,3054,2936,1647,1587,1477,1247,846cm-1;iHNMR(DMSO-d6)&1.18~1.45(m,10H,环丙-H和2xCH3),2.28(s,3H,N-CH3),2.68~3.27(m,15H,2xpiperazine-H),3.72(m,1H,环丙-H),4.62(q,2H,NCH2),7.38(d,1H,8國H),7.64,7.86(d,2H,2x5-H),8.78,8.94(s,2H,2x2-H);MS附/z:674(M+H);Anal,calcdforC35H37F3N803:C62.30,H5.53,N16.61;foundC62.48,H5.62,N16.88。实施例48制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-(1-乙基-6-氟-7-哌嗪小基_4_(1//)_萘啶酮_3-基]-1,3,4-噁二唑(48)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或依诺沙星酰肼11(1.9g,5.6rnrno1)与等摩尔的依诺沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物48,收率32%。mp235237。C;IR(KBr)v:3264,3007,2918,1632,1567,1464,1250,862cm—1;NMR(DMSO陽d6)&1.18~1.47(m,7H,环丙-H和CH3),2.26(s,3H,N-CH3),2.64~3.15(m,16H,2xpiperazine-H),3.77(m,1H,环丙國H),4.64~3.76(m,2H,NCH2),7.36(d,1H,8-H),7.65,7.72(d,2H,2x5陽H),8.82,9.14(s,2H,2x2-H);MS附/z:644(M+H);Anal,calcdforC33H35F2N903:C61.58,H5.48,N19.58;foundC61.74,H5.32,N19.77。实施例49制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-(1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(49)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或加替沙星酰肼12(1.9g,5.6mmol)与等摩尔的加替沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物49,收率17%。mp196~198°C;IR(KBr)v:3276,2864,1626,1547,1448,1257,876cm.1;&NMR(DMSO-d6)<5:1.22~1.46(m,11H,2x环丙-H和CH3),2.25(s,3H,N-CH3),2.66~3.17(m,15H,2xpiperazine-H),3.74~7.82(m,2H,2x环丙-H),7.34(d,1H,8-H),7.72,7.84(d,2H,2x5-H),8.86,8.92(s,2H,2x2-H);MSw/z:699(M+H);Anal,calcdforC37H40F2N8O4:C63.60,H5.77,N16.04;foundC63.82,H5.53,N16.25。实施例50制备2-[l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)-4-(l^)-喹啉酮-3-基]-5-[l-(4-氟苯基)-6-氟_7_(4-甲基哌嗪-1-基)-4-(1/0-喹啉酮-3-基]-1,3,4-噁二唑(50)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或二氟沙星酰肼13(2.4g,5.6mmol)与等摩尔的二氟沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物50,收率46%。mp252~254°C;IR(KBr)v:3266,2927,1633,1568,1476,1247,785cm";丄HNMR(DMSO-d6)&1.22~1.28(m,4H,环丙-H),2.24,2.36(s,6H,2xN-CH3),2.62~3.25(m,16H,2xpiperazine-H),3.77(m,1H,环丙-H),7.34(d,1H,8陽H),7.38~7.88(m,8H,2x5-H,2x8-HandPh-H),8.86,9.05(s,2H,2x2-H);MS附/z:723(M+H);Anal,calcdforC39H37F3N803:C64.81,H5.16,N15.50;foundC64.97,H5.33,N15.42。实施例51制备2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)_6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(51)以N-甲基环丙沙星酰肼4(2.0g,5.6mmol)或替马沙星酰肼14(2.4g,5.6mmol)与等摩尔的替马沙星或N-甲基环丙沙星为原料,按实施例41相同的制备方法可得化合物51,收率42%。mp257~259。C;IR(KBr)v:2936,1635,1573,1477,1264,786cm";丄HNMR(DMSO-d6)&1.22~1.26(m,7H,环丙-H和CH3),2.26,(s,3H,N-CH3),2.64~3.27(m,15H,2xpiperazine-H),3.68(m,1H,环丙-H),7.36~7.82(m,7H,2x5-H,2x8-HandPh-H),8.86,9.12(s,2H,2x2-H);MSm/z:741(M+H);Anal,calcdforC39H36F4N803:C63.24,H4.90,N15.13;foundC63.52,H4.81,N15.38。实施例52制备2,5-双[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(52)以恩诺沙星酰肼5(2.2g,6.0mmol)与等摩尔的恩诺沙星为原料,按实施例41相同的制备方法可得化合物52,收率36%。mp241~242°C;IR(KBr)v:3246,3017,2987,1634,1567,1455,1237cm-1;力NMR(DMSO-d6)&1.17~1.37(m,14H,2xCH3和2x环丙-H),2.27~2.31(m,4H,2xN-CH2),2.66~3.55(m,18H,2x环丙-H和哌嗪-H),7.34,7.42(d,2H,2x8-H),7.85(br,2H,2x5-H),8.82,8.87(s,2H,2x2-H);MS附/z:697(M+H);Anal,calcdforC38H42F2N803:C65.50,H6.08,N16.08;foundC65.72,H6.24,N16.32。实施例53制备(±)-2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(53)以恩诺沙星酰肼5(2.2g,6.0mmo1)或氧氟星酰肼6(2.3g,6.0mmol)与等摩尔的氧氟沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物53,收率44%。mp236~238°C;IR(KBr)v:3336,2857,1632,1537,1468,1208cm.1;'HNMR(DMS0隱d6)&1.18~1.46(m,10H,2xCH3和环丙-H),2.25~2.32(m,4H,2xN-CH2),2.38~3.64(m,17H,环丙-H和2x哌嗪-H),4.43~4.76(m,3H,OCH2和NCH),7.37(d,1H,8-H),7.85~8.14(br,2H,2x5隱H),8.84,9.05(s,2H,2x2-H);MS附/z:698(M+H);Anal,calcdforC37H40F2N8O4:C63.60,H5.77,N16.04;foundC63.82,H5.61,N16.27。实施例54制备(S)-2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(li/)-喹啉酮-3-基]-5-(8,l-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(54)以恩诺沙星酰肼5(2.2g,6.0mmoD或左氧氟星酰肼7(2.3g,6.0mmo1)与等摩尔的左氧氟沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物54,收率28%。mp217~219°C;IR(KBr)v:3247,2866,1633,1546,1482,1217cm";'HNMR(DMSO-d6)&1.16~1.48(m,10H,2xCH3和环丙-H),2.25-2.28(m,4H,2xN-CH2),2.58~3.66(m,17H,环丙陽H和2x哌嗪-H),4.47~4.76(m,3H,OCH2和NCH),7,44(d,1H,8國H),7.72~8.08(br,2H,2x5-H),8.85,9.06(s,2H,2x2-H);MSm/z:698(M+H);Anal,calcdforC37H40F2N8O4:C63.60,H5.77,N16.04;foundC63.76,H5,58,N16.26。实施例55制备2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(55)以恩诺沙星酰肼5(2.2g,6.0mmol)或芦氟沙星酰肼8(2.3g,6.0mmol)与等摩尔的芦氟沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物55,收率45%。mp246~248°C;IR(KBr)v:3327,2887,1636,1585,1464,1252cm";!H画R(DMSO-d6)<5:1.18~1.36(m,7H,CH3和环丙隱H),2.25~2.37(m,4H,2xN-CH2),2.64~3.58(m,19H,环丙-H,2x哌嗪-H和-SCH力,4.78(t,2H,噻嗪环-NCH2),7.42(d,1H,8-H),7.66,7.82(d,2H,2x5隱H),8.85~8.87(brs,2H,2x2-H);MS附/z:701(M+H);Anal,calcdforC36H38F2N803S:C61.70,H5.47,N15.99;foundC61.86,H5.57,N16.26。实施例56制备2-[l-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(2-氟乙基)-6,8-二氟_7_(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(56)以恩诺沙星酰肼5(2.2g,6.0mmo1)或氟罗沙星酰肼9(2.3g,6.0mmol)与等摩尔的氟罗沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物56,收率42%。mp235~237°C;IR(KBr)v:3257,2866,1627,1568,1458,1246cm-1;'HNMR(DMSO-d6)&1.22-1.34(m,7H,CH3和环丙-H),2.27~2.35(m,4H,2xN-CH2),2.68~3.66(m,17H,环丙-H和2x哌嗪-H),4.54(t,2H,NCH2),4.87(t,2H,FCH2),7.38(d,1H,8-H),7.64,7.88(d,2H,2x5-H),8.83~8.89(brs,2H,2x2邻;MSm/z:707(M+H);Anal,calcdforC36H38F4N803:C61.18,H5.42,N15.85;foundC61.34,H5.32,N15.97。实施例57制备2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(li/)-喹啉酮-3-基]-5-[l-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(57)以恩诺沙星酰肼5(2.2g,6.0mmoD或洛美沙星酰肼10(2.3g,6.0mmo1)与等摩尔的洛美沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物57,收率31%。mp212214。C;IR(KBr)v:3246,2947,1624,1557,1456,1238cm-1;画R(DMSO-d6)&1.221.37(m,10H,2xCH3和环丙-H),2.26(q,2H,N-CH2),2.823.45(m,16H,环丙-H和2x哌嗪-H),4.48(q,2H,NCH2),7.35(d,1H,8-H),7.66,7.84(d,2H,2x5-H),8.68~8.82(brs,2H,2x2-H);MSw/z:689(M+H);Anal,calcdforC36H39F3N803:C62.78,H5.71,N16.27;foundC62.65,H5.52,N16.56。实施例58制备2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(lH)-喹啉酮-3-基]-5-[l-乙基-6-氟-7-哌嗪-l-基-4-(l/Z)-萘啶酮-3-基H,3,4-噁二唑(58)以恩诺沙星酰肼5(2.2g,6.0mmoD或依诺沙星酰肼11(2.0g,6.0mmol)与等摩尔的依诺沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物58,收率24%。mp226228。C;IR(KBr)v:2937,1642,1617,1577,1453,1242cm-1;!HNMR(DMSO-d6)&1.22~1.37(m,10H,2xCH3和环丙-H),2.25(q,2H,N-CH2),2.74~3.55(m,17H,环丙-H和2x哌嗪誦H),4.55(q,2H,NCH2),7.37(d,1H,8陽H),7.66,8.12(d,2H,2x5-H),8.68~9.17(br,2H,2x2-H);MS/m/z:658(M+H);Anal,calcdforC34H37F2N903:C62.09,H5.67,N19.17;foundC62.28,H5.44,N19.42。实施例59制备2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-l-基)-4-(li7)-喹啉酮-3-基]-l,3,4-噁二唑(59)以恩诺沙星酰肼5(2.2g,6.0mmol)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物59,收率18%。mp206~208°C;IR(KBr)v:3456,2928,1638,1622,1553,1486,1247cm";NMR(DMSO-d6)(5:1.22~1.42(m,14H,2xCHs和2x环丙-H),2.26(q,2H,N-CH2),2.66~3.57(m,17H,2x环丙-H和2x哌嗪-H),3.88(s,3H,OCH3),4.57(q,2H,NCH2),7.42(d,1H,8陽H),7.68,7.76(d,2H,2x5-H),8.84~8.92(brs,2H,2x2-H);MS附/z:713(M+H);Anal,calcdforC38H42F2N904:C64.03,H5.94,N15.72;foundC64.22,H5.75,N15.62。实施例60制备2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(60)以恩诺沙星酰肼5(2.2g,6.0mmol)或替马沙星酰肼14(2.6g,6.0mmo1)与等摩尔的替马沙星或恩诺沙星为原料,按实施例41相同的制备方法可得化合物60,收率47%。mp255257。C;IR(KBr)v:3227,3008,2837,1646,1622,1566,1478,1255cm-1;'HNMR(DMSO-c4)&1.18~1.45(m,7H,2xCH3和环丙-H),2.24(q,2H,N-CH2),2.68~3.66(m,16H,环丙-H和2x哌嗪-H),4.62(q,2H,NCH2),7.38~7.88(m,7H,2x5-H,2x8陽HandPh陽H),8.87~9.12(brs,2H,2x2-H);MSw/z(%):755(M+H);Anal,calcdforC40H38F4N9O3:C63.65,H5.07,N14.85;foundC63.84,H5.22,N15.11。实施例61制备(±)-2,5-双{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-卜基)-4-(1均-喹啉酮-3-基}-1,3,4-噁二唑(61)氧氟沙星酰肼6(2.3g,6.0mmo1)与等摩尔的氧氟沙星(6.0mmo1)在50mL三氯氧磷中回流10小时,冷却至室温,减压蒸馏直到蒸干,剩余物用200mL冰水溶解,滤除不溶物,滤液用30y。的氢氧化钠水溶液调pH为10.5,收集产生的固体,水洗至中性,干燥,得粗品,将该粗品悬浮于50mL85。/。的乙醇中,用浓盐酸调pH值为5.0,然后加热溶解,静置冷却析出晶体,即得化合物61的盐酸盐,将产生的盐酸盐溶于去离子水中,用浓氨水碱化至pH为10.0,收集产生的固体,水洗至中性,干燥得黄色分析纯游离碱61,收率32%。mp226~228°C;IR(KBr)v:3336,2857,1632,1567,1468,1238cm.1;'HNMR(DMSO-d6)&1.40~1.45(m,6H,2xCH3),2.26(s,6H,2xN-CH3),2.47~3.26(m,16H,2x哌嗪-H),4.45~4.78(m,6H,2xOCH2和2xNCH),7.54(d,2H,2x5-H),8.96(s,2H,2x2隱H);MS701(M+H);Anal,calcdforC36H38F2N805:C61.71,H5.47,N15.99;foundC61.88,H5.28,N16.16。实施例62制备(S)-2,5-双{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(62)以氧氟沙星酰肼6(2.3g,6.0mmo1)或左氧氟沙星酰肼7(2.3g,6.0mmol)与等摩尔的左氧氟沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物62,收率27%。mp2U212。C;IR(KBr)v:3268,2847,1636,1582,1475,1254cm";'HNMR(DMSO-d6)<5:1.40~1.45(m,6H,2xCH3),2.25(s,6H,2xN-CH3),2.58~3.23(m,16H,2x哌嗪-H),4.45~4.82(m,6H,2xOCH2和2xNCH),7.55(d,2H,2x5-H),8.97(s,2H,2x2陽H);MSw/z:701(M+H);Anal,calcdforC36H38F2N805:C61.71,H5.47,N15.99;foundC61.84,H5.66,N16.14。实施例63制备(±)-2-{8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-l-基)-4-(lJ9)-喹啉酮-3-基}-5-[l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-l-基)-4-(lH)-喹啉酮-3-基]-l,3,4-噁二唑(63)以氧氟沙星酰肼6(2.3g,6.0mmol)或芦氟沙星酰肼8(2.3g,6.0mmol)与等摩尔的芦氟沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物63,收率37%。mp211212。C;IR(KBr)v:3266,2938,1627,1567,1455,1238cm.1;!HNMR(DMSO-d6)&1.43(m,3H,CH3),2.26~2.28(m,6H,2xN-CH3),2.57~3.58(m,18H,2x哌嗪-H和SCH2),4.46~4.88(m,8H,OCH2,NCH和噻嗪环-NCH2),7.46~7.58(brs,2H,2x5-H),8.84~9.03(br,2H,2x2-H);MSw/z:703(M+H);Anal,calcdforC35H36F2N804S:C59.82,H5.16,N15.94;foundC60.11,H5.07,N16.17。实施例64制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(64)以氧氟沙星酰肼6(2.3g,6.0mmol)或氟罗沙星酰肼9(2.3g,6.0mmol)与等摩尔的芦氟沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物64,收率37%。mp236238。C;IR(KBr)v:3274,2942,1633,1584,1453,1247cm";'H而R(DMSO-d6)3:1.44(m,3H,CH3),2.24~2.26(m,6H,2xN-CH3),2.62~3.25(m,16H,2x哌嗪-H),4.46~4.88(m,7H,OCH2,NCH,NCH2禾卩FCH2),7.42-7.88(m,2H,2x5-H),8.84~8.92(br,2H,2x2-H);MS附/z:709(M+H);Anal,calcdforC35H36F4N804:C59.32,H5.12,N15.81;foundC59.44,H5.02,N15.96。实施例65制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(65)以氧氟沙星酰肼6(2.3g,6.0mmo1)或洛美沙星酰肼10(2.3g,6.0mmo1)与等摩尔的洛美沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物65,收率16%。mp217219。C;IR(KBr)v:3436,2957,1632,1567,1455,1262cm";!HNMR(DMSO-d6)&1.37~1.43(m,9H,3xCH3),2.25(s,3H,N-CH3),2.64~3.27(m,15H,2x哌嗪-H),4.46~4.76(m,5H,OCH2>NCH,NCH2),7.44~7.74(m,2H,2x5陽H),8.84-8.86(br,2H,2x2-H);MS附/z:691(M+H);Anal,calcdforC35H37F4N804:C60.86,H5.40,N16.22;foundC60.76,H5.17,N16.38。实施例66制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基]-1,3,4-噁二唑(66)以氧氟沙星酰肼6(2.3g,6.0mmol)或依诺沙星酰肼11(2.0g,6.0mmol)与等摩尔的依诺沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物66,收率22%。mp225227。C;IR(KBr)v:3256,2943,1628,1574,1457,1255cm";NMR(DMSO-d6)<5:1.35~1.47(m,6H,2xCH3),2.26(s,3H,N-CH3),2.60~3.25(m,16H,2x哌嗪-H),4.45~4.84(m,5H,OCH2,NCH,NCH2),7.35~7.78(m,2H,2x5-H),8.87~8.94(brs,2H,2x2-H);MS660(M+H);Anal,calcdforC33H35F2N904:C60.08,H5.35,N19.11;foundC60.32,H5.12,N19.33。实施例67制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基}-5陽[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(67)以氧氟沙星酰肼6(2.3g,6.0mmol)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物67,收率14%。mp205~207°C;IR(KBr)v:3376,2958,1636,1586,1458,1257cm";^NMR(DMSO-d6)&1.18~1.42(m,10H,2xCH3和环丙-H),2.25(s,3H,N-CH3),2.48~3.15(m,15H,2x哌嗪-H),3.54(m,1H,环丙-H),3.86(s,3H,OCH3),4.46~4.87(m,3H,OCH2,NCH),7.37~7.76(m,2H,2x5-H),8.86~9.12(br,2H,2x2-H);MSm/z:715(M+H);Anal,calcdforC37H40F2N9O5:C62.17:H5.64,N15.68;foundC62.36,H5.47,N15.86。实施例68制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(4隱氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(68)以氧氟沙星酰肼6(2.3g,6.0mmol)或二氟沙星酰肼13(2.5g,6.0mmo1)与等摩尔的二氟沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物68,收率47%。mp256~258°C;IR(KBr)v:3258,2946,1632,1574,1457,1256cm";&NMR(DMSO-d6)&1.37~1.45(m,3H,CH3),2.25,2.27(s,6H,2xN-CH3),2.67~3.20(m,16H,2x哌嗪-H),4.46~4.76(m,3H,OCH2,NCH),7.37~7.88(m,7H,2x5-H,8-H和Ph陽H),8.86~9.16(brs,2H,2x2-H);MSw/z:739(M+H);Anal,calcdforC39H37F3N804:C63.41,H5.05,N15.17;foundC63.58,H5.16,N15.36。实施例69制备(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(69)以氧氟沙星酰肼6(2.3g,6.0mmo1)或替马沙星酰肼14(2.5g,6.0mmo1)与等摩尔的替马沙星或氧氟沙星为原料,按实施例61相同的制备方法可得化合物69,收率44%。mp253255。C;IR(KBr)v:3327,3015,2857,1644,1624,1568,1476,1258cm—1;^NMR(DMSO-d6)&1.35~1.45(m,6H,2xCH3),2.26(s,3H,N-CH3),2.66~3.23(m,15H,2x哌嗪-H),4.45-4.84(m,3H,OCH2,NCH),7.36~7.74(m,6H,2x5陽H,8-H和Ph國H),8.94~9.17(br,2H,2x2-H);MS附/z:757(M+H);Anal,calcdforC39H36F4N804:C61.90,H4.79,N14.81;foundC62.15,H4.62,N14.97。实施例70制备(S,S)-2,5-双{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(17/)-喹啉酮-3-基}-1,3,4-噁二唑(70)以左氧氟沙星酰肼7(2.3g,6.0mmo1)与等摩尔的左氧氟沙星为原料,按实施例61相同的制备方法可得化合物70,收率26%。mp215~217°C;IR(KBr)v:3258,3032,2866,1637,1617,1572,1468,1256cm";NMR(DMSO-d6)&1.35(d,6H,2xCH3),2.24(s,6H,2xN-CH3),2.58~3.17(m,16H,2x哌嗪-H),4.52~4.86(m,6H,2xOCH2和2xNCH2),7.46~7.78(m,2H,2x5-H),8.95(br,2H,2x2-H);MS附/z:701(M+H);Anal,calcdforC36H38F2N805:C61.71,H5.47,N15.99;foundC61.86,H5.68,N16.22。实施例71制备(S)-2-(8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-l-基)-4-(lH)-喹啉酮-3-基]-l,3,4-噁二唑(71)以左氧氟沙星酰肼7(2.3g,6.0mmo1)或芦氟沙星酰肼8(2.3g,6.0mmol)与等摩尔的芦氟沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物71,收率35%。mp238240。C;IR(KBr)v:3264,3017,2836,1635,1624,1567,1472,1268cm";&NMR(DMSO-d6)&1.37(d,3H,CH3),2.26(s,6H,2xN-CH3),2.56~3.35(m,16H,2x哌嗪-H),4.52~4.88(m,5H,OCH2,NCH和SCH2),7.42,7.86(d,2H,2x5-H),8.92,9.05(s,2H,2x2-H);MSm/z:703(M+H);Anal,calcdforC35H36F2N804S:C59.82,H5.16,N15.94;foundC59.74,H5.33,N16.14。实施例72制备(S)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑C72)以左氧氟沙星酰肼7(2.3g,6.0mmol)或氟罗沙星酰肼9(2.3g,6.0mmol)与等摩尔的氟罗沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物72,收率32%。mp228230。C;IR(KBr)v:3342,3037,2946,1627,1546,1476,1258cm—1;^NMR(DMSO-de)&1.35(d,3H,CH3),2.26,2.32(s,6H,2xN-CH3),2.64~3.27(m,16H,2x哌嗪-H),4.46~4.82(m,7H,OCH2,NCH,FCH2fHNCH2),7.45,7.84(d,2H,2x5-H),8.86,9.13(s,2H,2x2陽H);MSm/z:709(M+H);Anal,calcdforC35H36F4N804:C59.32,H5.12,N15.81;foundC59.47,H5.38,N16.06。实施例73制备(S)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(73)以左氧氟沙星酰肼7(2.3g,6.0mmo1)或洛美沙星酰肼10(2.3g,6.0mmol)与等摩尔的洛美沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物73,收率18%。mp210~212°C;IR(KBr)v:3276,2938,1636,1568,1464,1257cm";NMR(DMSO-d6)(5:1.37~1.44(m,6H,2xCH3),2.25(s,3H,N-CH3),2.62-3.17(m,15H,2x哌嗪-H),4.45~4.72(m,5H,OCH2,NCH和NCH2),7.45,7.74(d,2H,2x5陽H),8.86,9.15(s,2H,2x2-H);MSm/z:691(M+H);Anal,calcdforC35H37F4N804:C60.86,H5.40,N16.22;foundC60.74,H5.16,N16.38。实施例74制备(S)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基}-5-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基]-1,3,4-噁二唑(74)以左氧氟沙星酰肼7(2.3g,6.0mmol)或依诺沙星酰肼11(2.0g,6.0mmol)与等摩尔的依诺沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物74,收率27%。mp216~218。C;IR(KBr)v:3342,3036,2935,1633,1468,1267cm";!H画R(DMSO-d6)1.38-1.46(d,6H,2xCH3),2.24(s,3H,N-CH3),2.66~3.25(m,16H,2x哌嗪隱H),4.45~4.77(m,5H,OCH2,NCH和NCH2),7.44,7.86(d,2H,2x5-H),8.86,9.17(s,2H,2x2-H);MSm/z:660(M+H);Anal,calcdforC33H35F2N904:C60.08,H5.35,N19.11;foundC60.26,H5.14,N19.34。实施例75制备(S)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(75)以左氧氟沙星酰肼7(2.3g,6.0mmol)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物75,收率24%。mp213~214°C;IR(KBr)v:3348,3032,2896,1627,1568,1275cm";'HNMR(DMSO-d6)&1.18~1.45(m,10H,环丙-H和2xCH3),2.26(s,3H,N-CH3),2.65~3.17(m,15H,2x哌嗪-H),3.56~3.67(m,1H,环丙-H),4.45~4.74(m,3H,OCH2禾口NCH),7.36~7.84(m,2H,2x5-H和8-H),8.86,8.卯(s,2H,2x2-H);MSw/z:685(M+H);Anal,calcdforC36H38F2N804:C63.15,H5.59,N16.36;foundC63.40,H5.38,N16.52。实施例76制备(S)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1印-喹啉酮-3-基卜5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(76)以左氧氟沙星酰肼7(2.3g,6.0mmol)或二氟沙星酰肼13(2.5g,6.0mmol)与等摩尔的二氟沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物76,收率26%。mp220~222°C;IR(KBr)v:3256,2938,1635,1576,1456,1257cm";&画R(DMSO-d6)&1.37~1.46(m,3H,CH3),2.24,2.27(s,6H,2xN-CH3),2.67~3.23(m,16H,2x哌嗪-H),4.46~4.82(m,3H,OCH2,NCH),7.35-7.86(m,7H,2x5-H,8-H和Ph-H),8.869.13(br,2H,2x2陽H);MS附/z:739(M+H);Anal,calcdforC39H37F3N804:C63.41,H5.05,N15.17;foundC63.62,H5.22,N15.30。实施例77制备(S)-2-(8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(77)以左氧氟沙星酰肼7(2.3g,6.0mmol)或替马沙星酰肼14(2.5g,6.0mmo1)与等摩尔的替马沙星或左氧氟沙星为原料,按实施例61相同的制备方法可得化合物69,收率44%。mp238239。C;IR(KBr)v:3337,3036,2935,1638,1612,1567,1465,1257cm—1;!HNMR(DMSO-d6)<5:1.36~1.47(m,6H,2xCH3),2.26(s,3H,N-CH3),2.62~3.30(m,15H,2x哌嗪-H),4.46~4.86(m,3H,OCH2,NCH),7.35~7.76(m,6H,2x5-H,8-H和Ph-H),8.94~9.15(brs,2H,2x2-H);MS附/z:757(M+H);Anal,calcdforC39H36F4N804:C61.90,H4.79,N14.81;foundC62.18,H4.57,N14.63。实施例78制备2,5-双{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(78)以芦氟沙星酰肼8(2.3g,6.0mmo1)与等摩尔的芦氟沙为原料,按实施例61相同的制备方法可得化合物78,收率52%。mp260~262°C;IR(KBr)v:3248,3037,2854,1626,1567,1472cm";!H-NMR&2.42(s,6H,2xCH3),2.57~3.66(m,18H,2x哌嗪-H和SCH2),4.74(t,4H,2xNCH2),7.76(d,2H,2x5隱H),8.87(s,2H,2x2-H);MS附/z:705(M+H);Anal,calcdforC34H34F2N803S2:C57.94,H4.86,N15.90;foundC60.16,H4.62,N16.15。实施例79制备2-{l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-l-基)-4-(l/i)-喹啉酮-3-基]-l,3,4-噁二唑(79)芦氟沙星酰肼8(2.3g,6.0mmo1)或氟罗沙星酰肼9(2.3g,6.0mmol)与等摩尔的氟罗沙星或芦氟沙星为原料,按实施例61相同的制备方法可得化合物79,收率46%。mp238240。C;IR(KBr)v:3252,3038,2867,1624,1573,1456cm";!H-NMR^:2.36,2.38(s,6H,2xCH3),2.64~3.66(m,18H,2x哌嗪-H和SCH2),4.75,4.88(m,6H,2xNCH2和FCH2),7.64,7.82(d,2H,2x5誦H),8.87~8.89(brs,2H,2x2陽H);MS附/z:711(M+H);Anal,calcdforC34H34F4N803S:C57.46,H4.82,N15,77;foundC57.64,H4.63,N15.87。实施例80制备2-{l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(80)芦氟沙星酰肼8(2.3g,6.0mmol)或洛美沙星酰肼10(2.3g,6.0mmo1)与等摩尔的洛美沙星或芦氟沙星为原料,按实施例61相同的制备方法可得化合物80,收率25%。mp217~218°C;IR(KBr)v:3246,2936,1627,1582,1468cm";!H-NMR山1.37(s,6H,2xCH3);2.27(s,3H,NCH3),2.65~3.62(m,17H,2x哌嗪隱H和SCH2),4.86(m,2H,NCH2),7.53~7.76(m,2H,2x5邻,8.86~8.97(brs,2H,2x2國H);MS附/z:693(M+H);Anal,calcdforC34H35F3N803S:C58.95,H5.09,N16.17;foundC59.14,H4.78,N16.33。实施例81制备2-{l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基]-1,3,4-噁二唑(81)芦氟沙星酰肼8(2.3g,6.0mmoD或依诺沙星酰肼11(2.0g,6.0mmol)与等摩尔的依诺沙星或芦氟沙星为原料,按实施例61相同的制备方法可得化合物81,收率26%。mp225~227°C;IR(KBr)v:3238,2945,1625,1567,1458,1248cm-1;^-NMR^:1.44(t,3H,CH3),2.26(s,3H,NCH3),2.76~3.68(m,18H,2x哌嗪-H和SCH2),4.74~4.86(m,4H,2xNCH2),7.52~7.82(m,2H,2x5-H),8.869.14(br,2H,2x2-H);MSm/z:662(M+H);Anal.calcdforC32H33F2N903S:C58.08,H5.03,N19.05;foundC58.27,H4.88,N19.32。实施例82制备2-{l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(82)芦氟沙星酰肼8(2.3g,6.0rmno1)或加替沙星酰肼12(2.3g,6.0mmol)与等摩尔的加替沙星或卢氟沙星为原料,按实施例61相同的制备方法可得化合物82,收率18%。mp217219。C;IR(KBr)v:3324,3016,2875,1626,1565,1268cm";^-NMR^1.17~1.43(t,7H,环丙-H禾口CH3),2.27(s,3H,NCH3),2.62~3.68(m,19H,2x哌嗪國H,SCH2和NCH),3.86(s,3H,OCH3),4.87(q,2H,NCH2),7.38~7.84(m,2H,2x5-H),8.87~9.02(brs,2H,2x2-H);MS附/z:705(M+H);Anal,calcdforC35H38F2N804S:C59.65,H5.43,N15.90;foundC59.86,H5.27,N16.17。实施例83制备2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(4-氟苯基)-6-氟-7_(4-甲基哌嗪-1-基)-4-(1印-喹啉酮-3-基]-1,3,4-噁二唑(83)芦氟沙星酰肼8(2.3g,6.0mmol)或二氟沙星酰肼13(2.5g,6.0mmol)与等摩尔的二氟沙星或戸氟沙星为原料,按实施例61相同的制备方法可得化合物83,收率47%。mp262264。C;IR(KBr)v:3245,2964,3027,1632,1568,1457,1268cm-1;!H-丽R^2.26,2.32(s,6H,2xNCH3),2.57-3.72(m,18H,2x哌嗪-H和SCH2),4.84(q,2H,NCH2),7.68~7.84(m,6H,2x5-H,8-H和Ph-H),8.95,9.14(s,2H,2x2-H);MS附/z:741(M+H);Anal,calcdforC38H34F3N803S:C61.61,H4.76,N15.13;foundC61.82,H4.60,N15.40。实施例84制备2-{l,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2,4-二氟苯基)_6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(84)芦氟沙星酰肼8(2.3g,6.0mrno1)或替马沙星酰肼14(2.6g,6.0mmol)与等摩尔的替马沙星或戸氟沙星为原料,按实施例61相同的制备方法可得化合物84,收率50%。mp264265。C;IR(KBr)v:3238,2946,3017,1626,1567,1468,1243cm";H-NMRA1.38(d,3H,CH3),2.25(s,3H,NCH3),2.64~3.81(m,17H,2x哌嗪-H和SCH2),4.86(q,2H,NCH2),7.66~7.87(m,5H,2x5-H,8-H和Ph-H),8.97,9.15(s,2H,2x2-H);MS附/z:759(M+H);Anal,calcdforC38H33F4N803S:C60.15,H4.52,N14.77;foundC60.38,H4.66,N14.53。实施例85制备2,5-双[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(85)氟罗沙星酰肼9(2.3g,6.0mmol)与等摩尔的氟罗沙星为原料,按实施例61相同的制备方法可得化合物85,收率43%。mp242~244°C;IR(KBr)v:3267,2928,1627,1582,1473,1266cm—1;!H陽NMR&2.32(s,6H,2xCH3),2.74~3.58(m,16H,2x哌嗪-H),4.58(q,2H,NCH2),4.88(t,2H,FCH2),7.86(br,2H,2x5-H),8.96(s,2H,2x2邻;MS附/二,717(M+H);Anal,calcdforC34H34F6N803:C56.98,H4.78,N15.63;foundC57.25,H4.60,N15.82。实施例86制备2,5-双[l-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(86),6.0mmol)与等摩尔的洛美沙星为原料,按实施例61相同的制备方法可得化合物86,收率25%。mp215217。C;IR(KBr)v:3347,2927,1634,1583,1462,1258cm-1;'H-NMRJ:1.38~1.43(d,12H,4xCH3),2.56~3.27(m,14H,2x哌嗪-H),4.62(q,2H,NCH2),7.76(brs,2H,2x5-H),8.97(s,2H,2x2-H);MSw/z:681(M+H);Anal,calcdforC34H36F6N803:C59.99,H5.33,N16.46;foundC60.17,H5.48,N16.72。实施例87制备2,5-双[l-乙基-6-氟-7-哌嗪-l-基-4-(l^)-萘啶酮-3-基]-l,3,4-噁二唑(87)依诺沙星酰肼ll(2.0g,6.0mmol)与等摩尔的依诺沙星为原料,按实施例61相同的制备方法可得化合物87,收率32%。mp225~227°C;IR(KBr)3342,3037,2928,1635,1475,1267cm—1;'H-NMRA1.35(t,6H,2xCH3),2.66~3.24(m,16H,2x哌嗪-H),4.54(q,2H,NCH2),7.80(brs,2H,2x5-H),9.15(s,2H,2x2-H);MSw/z:619(M+H);Anal,calcdforC30H32F2N10O3:C58.25,H5.21,N22.64;foundC58.46,H5.05,N22.88。实施例88制备2,5-双[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(88)加替沙星酰肼12(2.3g,6.0mrno1)与等摩尔的加替沙星为原料,按实施例61相同的制备方法可得化合物88,收率23%。mp213~214°C;IR(KBr)v:3276,3005,2875,1625,1567,1258cm";'H隱NMRAl,15~1.37(m,14H,2x环丙-H和2xCH3),2.55~3.12(m,14H,2x哌嗪-H),3.52~3.74(m,2H,2x环丙-H),3.88(s,6H,2xOCH3),7.83(br,2H,2x5-H),9.02(s,2H:2x2-H);MSw/z:729(M+H);Anal,calcdforC38H42F2N10O5:C62.63,H5.81,N15.37;foundC62.82,H5.65,N15.52。实施例89制备2,5-双[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(89)二氟沙星酰肼13(2.5g,6.0mrno1)与等摩尔的二氟沙星为原料,按实施例61相同的制备方法可得化合物89,收率46%。mp258~260°C;IR(KBr)v:3342,3025,2967,2836,1625,1557,1468,1265cm";!H-NMRA2.30(s,6H,2xCH3),2.77~3.35(m,16H,2x哌嗪-H),7.66~7.82(m,12H,2x5-H,2x8-Hand2xPh-H),9.08(s,2H,2x2國H);MSw/z:777(M+H);Anal,calcdforC42H36F4N803:C64.94,H4.67,N14.43;foundC65.16,H4.84,N14.66。实施例90制备2,5-双[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1/0-喹啉酮-3-基]-1,3,4-噁二唑(卯)替马沙星酰肼14(2.6g,6.0mmol)与等摩尔的替马沙星为原料,按实施例61相同的制备方法可得化合物卯,收率57%。mp260262。C;IR(KBr)v:3347,3028,3018,2937,1632,1566,1457,1268cm.1;'H-NMR3:1.36(d,6H,2xCH3),2.80~3.27(m,14H,2x哌嗪-H),7.757.88(m,10H,2x5-H,2x8-Hand2xPh-H),9.15(s,2H,2x2國H);MSm/z:813(M+H);Anal,calcdforC42H34F6N803:C62.07,H4.22,N13.79;foundC62.27,H4.02,N13.92。通过下面的生物学试验说明本发明化合物的活性。生物学试验1、实施例中制得的化合物的细胞毒活性测定以实施例15到实施例90中合成的76个新化合物及经典抗肿瘤TOPO抑制剂10-羟基喜树碱(Hydroxycamptodiecine,HPT)为供试样品,用二甲基亚砜(DMSO)配成l.Oxl(T2Hmol七"浓度的储备液,用10%小牛血清的RPMI-1640培养液按10倍稀释法稀释到所需的5个浓度梯度,取对数生长期的中国仓鼠卵巢(CHO)细胞以每孔5000个细胞接种于96孔板,培养隔夜后,加入不同浓度的上述供试样品,48小时后弃去培养基,每孔加入lg七-1的溴化四氮唑蓝(MTT)溶液100^L,继续培养4小时后弃去上清液,每孔加入150uL的DMSO,轻轻振荡30分钟,用酶标仪在570nm波长处测其吸光度(OD)值;再取对数生长期的人白血病细胞(HL60)和鼠白血病细胞(L1210),以每孔7000个细胞接种于96孔板,随后加入不同浓度的上述供试样品,48小时后每孔加入5g七-1的MTT溶液IOliL,继续培养4小时后加入10%SDS(十二垸基硫酸钠)溶液100nL培养过夜,用酶标仪在570nm波长处测其OD值。按下列公式计算出各浓度对癌细胞的抑制率,然后以各药物浓度对数值对各浓度下的细胞抑制率作线性回归,从所得剂量一效应方程计算出各供试化合物对实验癌细胞的平数抑制浓度(/C50),测定数据见表l。细胞抑制率=(1一实验组吸光度值/对照组吸光度值"100%表1氟喹诺酮二聚体衍生物15~90的抗肿瘤活性(IC5o)测定数据0Q编号XRR2R3YR2,R3'IC50,CHOHL60L121015CHC2H5HHCHC2H5HH15.620.57.616CHC2H5HHCHC2H5CH3H24.842.48.617CHC2H5HHCH环丙基HH7.512.42.718CHC2H5HHCH环丙基CH3H12.615.59.419CHC2H5HH(±)C-OCH2(CH3)CHCH3H53.674.248.620CHC2H5HH(S)C-OCH2(CH3)CHCH3H5.57.62.221CHC2H5HHC-SCH2CH2CH3H57.438.622.622CHC2H5HHC-FFCH2CH2CH3H10.45.63.823CHC2H5HHC-FCH2CH3HCH350.575.322.424CHC2H5HHNCH2CH3HH10.615.74.525CHC2H5HHC-OCH3环丙基HCH34.68.22.726CHC2H5HHCHC-4-FC6H4CH3H55.6120.457.5<table>tableseeoriginaldocumentpage36</column></row><table><table>tableseeoriginaldocumentpage37</column></row><table>477(S)C-OCH2(CH3)CHCH3HCHC-2,4-F2CHCH35.62.82.078C-SCH2CH2CH3HC-SCH2CH2CH3H56.372.555.479C-SCH2CH2CH3HC-FFCH2CH2CH3H12.828.67.480C-SCH2CH2CH3HC-FCH2CH3HCH323.634.712.581C-SCH2CH2CH3HNCH2CH3HH6.615.75.082C-SCH2CH2CH3HC-OCH3环丙基HCH32.78.26.383C-SCH2CH2CH3HCHC-4-FC6H4CH3H>100>10062.484C-SCH2CH2CH3HCHC-2,4-F2C6H3HCH377.658.236.285C-FFCH2CH2CH3HCHFCH2CH2CH3H3.57.63.286C-FCH2CH3HCH3C-FCH2CH3HCH315.722.512.887NCH2CH3HHNCH2CH3HH1.53.00.6288C-OCH3环丙基HCH3C-OCH3环丙基HCH31.72.61.0089CHC-4-FC6H4CH3HCHC-4-FC6H4CH3H50.472.835.790C-FC-2,4-F2CfiH3CH3HC-FC-2,4-F2CCH3H2.77.42.4HPT3.67.21.50注试剂来源MTT为Sigma公司产品,RPMI-1640培养为GIBCO公司产品,其他为国产分析纯试齐IJ;癌细胞株CHO、HL60及L1210均购买自中国科学院上海细胞库。表中每个数据平行测定三次,取其平均值。以上实验数据表明,本发明的氟喹诺酮二聚体衍生物对实验白血病癌细胞株具有强的细胞毒作用。其中环丙系列和左氧氟系列化合物的细胞毒活性与对照io-羟基喜树碱的活性相当,部分化合物的活性优于对照。按照药物开发的一般途径是先进行常规的抗肿瘤体外筛选,然后进行针对性的研究,所以本发明的化合物具有强的抗肿瘤活性,可通过与人体可接受的酸成盐或与药用载体混合制备抗肿瘤药物。2、实施例中制得的环丙系列和左氧氟系列化合物的抗菌活性测定供试化合物及对照药环丙沙星(CF)和左氧氟沙星(LOF)预配成128ng'mi;1的DMSO溶液作为供试样品,采用标准平皿二倍稀释法(王秀云等,药学学报,2008,W,819.)测定其对金黄色葡萄球菌(S.awreM力ATCC25923、枯草芽孢杆菌(S.仰fon'fe)ATCC63501、大肠埃希氏菌(五.co//)ATCC25922和铜绿假单孢菌(i5.aeragz'朋ja)ATCC27853的体外最低抑制菌浓度(MICs),结果见表2。表2氟喹诺酮二聚体衍生物的抗菌活性测定数据(MIC^g,mL—1)<table>tableseeoriginaldocumentpage39</column></row><table><table>tableseeoriginaldocumentpage40</column></row><table>注样品编号同表1;试剂来源培养基为杭州天和微生物试剂生产的水解酪蛋白琼脂(MH琼脂),其他为国产分析纯试剂;标准菌株均购买自中国科学院微生物研究所;表中每个数据平行测定三次,取其平均值。以上抗菌实验数据表明,本发明的氟喹诺酮二聚体衍生物对实验金黄色葡萄球菌(S.aureus)ATCC25923、枯草芽孢杆菌(B.substilis)ATCC63501、大肠埃希氏菌(E.coli)ATCC25922和铜绿假单孢菌(P.aeruginosa)ATCC27853具有一定的生长抑制作用。虽然对黄色葡萄球菌、枯草芽孢杆菌及铜绿假单孢菌的活性不及对照环丙沙星(CF)和左左氧氟沙星(LOF),但对革兰阴性大肠埃希氏菌的抑制活性与对照的活性相当,部分化合物的活性优于对照。按照药物开发的一般途径是先进行常规的体外筛选,然后进行针对性的研究,所以本发明的化合物具有潜在的抗菌活性,可直接或通过与人体可接受的酸成盐或与药用载体混合制备抗感染药物。权利要求1、一种以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其特征在于,所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物为具有如下结构通式(I)的化合物其中R1和R1′为任选被独立地选自H、(C1-C10)烷基、(C3-C10)环烷基、(C1-C10)卤代烷基、取代的芳香烃基或取代的杂环芳香烃基;R2和R2′为任选被独立地选自H、(C1-C7)烷基、(C3-C7)环烷基、取代的芳香烃基、取代的杂环芳香烃基、烃类酰基或磺酰基;R3和R3′为任选被独立地选自H、(C1-C5)烷基、(C3-C5)环烷基、取代的芳香烃基或取代的杂环芳香烃基;X和Y为任选被独立地选自(a)CH;(b)N;或(c)与卤素、烃基、烃氧基、烃硫基、氨基、取代氨基、取代的芳香烃基或取代的杂环芳香烃基相连的碳原子。2、根据权利要求1所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其特征在于,R,和X、R卩和Y可同时或独立地构成五元、六元或七元的饱和或不饱和硫、氧、氮杂环。3、根据权利要求1所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其特征在于,R,和R/独立地优选为乙基、环丙基、FCH2CH2_、单氟代苯基或二氟代苯基;R2和R2'独立地优选为H、甲基或乙基;R3和R3'独立地优选为H或甲基;X和Y独立地优选为CH、N、与氟相连的碳原子或与甲氧基相连的碳原子。4、根据权利要求2所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其特征在于,优选地,Rt和X、R和Y可同时或独立地构成六元饱和硫、氧、氮杂环。5、根据权利要求1所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物,其特征在于,所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物为2,5-双[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为15);2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6-氟-7-(4-甲基哌嗪)_1_基_4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为16);2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1均-喹啉酮-3-基)-5-(1-环丙基-6-氟-7-哌嗪-1-基-4-(l^)-喹啉酮-3-基)-l,3,4-噁二唑(代号为17);2-(l-乙基-6-氟-7-哌嗪-l-基-4-(l^)-喹啉酮-3-基)-5-[l-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为18);(±)-2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1均-喹啉酮-3-基)-5-{8,l-[l,2-(氧丙基)-6-氟_7_(4-乙基哌嗪-1-基)-4-(1均-喹啉酮-3-基]-1,3,4-噁二唑(代号为19);(S)-2-(l-乙基-6-氟-7-哌嗪-l-基-4-(17/)-喹啉酮-3-基)-5-(8,l-[l,2-(氧丙基)-6-氟_7一(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为20);2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[8,1-(硫乙基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//>喹啉酮-3-基]-1,3,4-噁二唑(代号为21);2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(17/)-喹啉酮-3-基]-1,3,4-噁二唑(代号为22);2-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基)-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,44惡二唑(代号为23);2-[l-乙基-6-氟-7-哌嗪-l-基-4-(l印-喹啉酮-3-基]-5-[l-乙基-6-氟-7-哌嗪-l-基_4-(1//)-萘啶酮-3-基]-l,3,44惡二唑(代号为24);2-[l-乙基-6-氟-7-哌嗪-l-基-4-(l^-喹啉酮-3-基]-5-[l-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1用喹啉酮-3-基]-1,3,4-噁二唑(代号为25);2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-l-基)-4-(Lf/)-喹啉酮-3-基]-l,3,4-噁二唑(代号为26);2-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为27);2,5-双[1-环丙基-6-氟-7-哌嗪-1-基-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(代号为28);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(177)-喹啉酮-3-基]-5-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为29);2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(l/f)-喹啉酮-3-基]-5-[l-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,44惡二唑(代号为30);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为31);(±)-2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1^)-喹啉酮-3-基]-5-{8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(代号为32);(S)-2-[l-环丙基-6-氟-7-哌嗪-l-基-4-(l/7)-喹啉酮-3-基]-5-(8,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(代号为33);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[8,l-(硫乙基)-6-氟_7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为34);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-0氟乙基)-6,8-二氟_7_(4_甲基哌嗪小基)-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(代号为35);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-l-基)-4-(l/7)-喹啉酮-3-基]-l,3,44惡二唑(代号为36);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-(1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基)-1,3,4-噁二唑(代号为37);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-环丙基-6-氟-8-甲氧基-7一(3_甲基一哌嗪_1_基)_4-(1//)-喹啉酮-3-基)-1,3,4-噁二唑(代号为38);*2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1//)-喹啉酮-3-基]-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基)-1,3,4-噁二唑(代号为39);2-[1-环丙基-6-氟-7-哌嗪-1-基-4-(1均-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6画氟-7-(3-甲基哌嗪-1-基)-4-(1用-喹啉酮-3-基)-1,3,4-噁二唑(代号为40);2,5-双[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1印-喹啉酮-3-基]-1,3,4-噁二唑(代号为41);2-(l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)-4-(l用-喹啉酮-3-基)-5-[l-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为42);(±)-2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-l-基)-4-(l均-喹啉酮-3-基]-l,3,4-噁二唑(代号为43);(S)-2-[l-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[8,1-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-l-基)-4-(l均-喹啉酮-3-基]-l,3,4-噁二唑(代号为44);2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-5-[1,8-(乙硫基)_6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为45);2-[l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)-4-(Lft0-喹啉酮-3-基]-5-[l-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为46);2-[l-环丙基-6-氟-7-(4-甲基哌嗪-l-基)-4-(l均-喹啉酮-3-基]-5-[l-乙基-6,8-二氟_7_(3_甲基哌嗪_1_基)_4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为47);.2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1均-喹啉酮-3-基]-5-(1-乙基-6-氟-7-哌嗪-l-基-4-(l/f)-萘啶酮-3-基]-l,3,4-噁二唑(代号为48);2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-(1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为49);'2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(4-氟苯基)-6-氟_7_(4-甲基哌嗪-1-基)-4-(1/7)-喹啉酮-3-基]-1,3,4-噁二唑(代号为50);*2-[1-环丙基-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为51);2,5-双[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1/7)-喹啉酮-3-基]-1,3,4-噁二唑(代号为52);(±)-2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4(1//)-喹啉酮-3-基]-5-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4(1用-喹啉酮-3-基}-1,3,4-噁二唑(代号为53);(S)-2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(L^)-喹啉酮-3-基]-5-(8,l-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-1,3,4-噁二唑(代号为54);2_[1_环丙基_6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为55);2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(Lf/)-喹啉酮-3-基]-5-[l-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-l-基)-4-(l^)-喹啉酮-3-基]-l,3,4-噁二唑(代号为56);2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为57);2-[1-环丙基-6-氟-7-(4-乙基哌嗪-1-基)-4-(1/^-喹啉酮-3-基]-5-[1-乙基-6-氟-7-哌嗪-1-基-4-(1//)-萘啶酮-3-基]-1,3,4-噁二唑(代号为58);2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(17/)-喹啉酮-3-基]-5-[l-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(代号为59);2-[l-环丙基-6-氟-7-(4-乙基哌嗪-l-基)-4-(17i)-喹啉酮-3-基]-5-[l-(2,4-二氟苯基)_6-氟-7-(3-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,44惡二唑(代号为60);(±)-2,5-双{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮画3-基卜l,3,4-噁二唑(代号为61);(S)-2,5-双(8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-l-基)-4-(l/7)-喹啉酮-3-基卜l,3,4-噁二唑(代号为62);*(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-1,3,4-噁二唑(代号为63);'(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1均-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为64);'(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-l-基)-4-(l/7)-喹啉酮-3-基]-l,3,4-噁二唑(代号为65);'(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基-6-氟-7-哌嗪-l-基-4-(l/7)-萘啶酮-3-基]-l,3,4-噁二唑(代号为66);争(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1/^)-喹啉酮-3-基}-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-l-基)-4-(l坊-喹啉酮-3-基]-l,3,4-噁二唑(代号为67);(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为68);(±)-2-{8,1-[1,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//>喹啉酮-3-基}-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基]-1,3,44惡二唑(代号为69);(8,8)-2,5-双{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1/7)-喹啉酮-3-基卜l,3,4-噁二唑(代号为70);(S)-2-(8,l-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-l-基)-4-(17/)-喹啉酮-3-基卜5-[1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为71);'(5)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为72);'(8)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1/7)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-l-基)-4-(l/7)-喹啉酮-3-基]-l,3,4-噁二唑(代号为73);'(8)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-乙基_6_氟_7_哌嗪_1_基_4-(1//)-萘啶酮-3-基]-1,3,44惡二唑(代号为74);*(8)-2-{8,1-[2,3-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-l-基)-4-(l/i)-喹啉酮-3-基]-l,3,4-噁二唑(代号为75);(S)-2-{8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(l用-喹啉酮-3-基}-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为76);(S)-2-{8,l-[l,2-(氧丙基)]-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基}-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4(1^)-喹啉酮-3-基]-1,3,4-噁二唑(代号为77);2,5-双{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基}-1,3,44惡二唑(代号为78);2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1均-喹啉酮-3-基}-5-[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1均-喹啉酮-3-基]-1,3,4-噁二唑(代号为79);2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基}-5-[1-乙基-6,8-二氟-7-(3-甲基哌嗪-l-基)-4-(l/f)-喹啉酮-3-基]-l,3,4-噁二唑(代号为80);2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基}-5-[1-乙基-6-氟-7_哌嗪_1_基_4(1//)-萘啶酮-3-基]-1,3,44惡二唑(代号为81);2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基}-5-[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为82);2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基}-5-[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为83);'2-{1,8-(乙硫基)-6-氟-7-(4-甲基哌嗪-1-基)-4(1^-喹啉酮-3-基}-5-[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为84);*2,5-双[1-(2-氟乙基)-6,8-二氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为85);2,5-双[1-乙基-6,8-二氟-7-(3-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-1,3,44惡二唑(代号为86);2,5-双[1-乙基-6-氟-7-哌嗪-1-基-4-(1用-萘啶酮-3-基]-1,3,4-噁二唑(代号为87);2,5-双[1-环丙基-6-氟-8-甲氧基-7-(3-甲基-哌嗪-1-基)-4-(1^-喹啉酮-3-基]-l,3,4-噁二唑(代号为88);'2,5-双[1-(4-氟苯基)-6-氟-7-(4-甲基哌嗪-1-基)-4-(1//)-喹啉酮-3-基]-1,3,4-噁二唑(代号为89);2,5-双[1-(2,4-二氟苯基)-6-氟-7-(3-甲基哌嗪-1-基)-4-(1^)-喹啉酮-3-基]-l,3,4-噁二唑(代号为90)。6、一种如权利要求1所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物的制备方法,其特征在于,该方法包括如下步骤(1)将结构通式(II)的化合物溶于80%的水合肼,回流反应1224小时,冷却至室温,之后减压蒸馏直到蒸干,剩余物用水、无水乙醇或二者的混合溶剂重结晶,得到结构通式(III)的化合物;(2)结构通式(III)的化合物再与结构通式(IV)的化合物在三氯氧磷中回流反应612小时,冷却至室温,减压蒸馏直到蒸干,剩余物用冰水溶解,滤除不溶物,滤液调pH值为9.510.5,收集产生的固体,水洗至中性,干燥,得目标化合物(I)的粗品,将该粗品悬浮于85%乙醇中,调pH值为3.5-5.0,然后加热溶解,静置冷却后析出晶体,即目标化合物(I)的盐,将产生的盐溶于水中,碱化至pH值为9.010.0,收集产生的固体,水洗至中性,干燥即得目标化合物(I)的纯品;<formula>formulaseeoriginaldocumentpage9</formula>其中Rt和RZ为任选被独立地选自H、(d-do)烷基、(C3-do)环烷基、(d-do)卤代烷基、取代的芳香烃基或取代的杂环芳香烃基;R2和R2'为任选被独立地选自H、(Q-C7)垸基、(Q-C7)环垸基、取代的芳香烃基、取代的杂环芳香烃基、烃类酰基或磺酰基;R3和R3'为任选被独立地选自H、(C广C5)垸基、(C3-C5)环垸基、取代的芳香烃基或取代的杂环芳香烃基;X和Y为任选被独立地选自(a)CH;(b)N;或(c)与卤素、烃基、烃氧基、烃硫基、氨基、取代氨基、取代的芳香烃基或取代的杂环芳香烃基相连的碳原子。7、根据权利要求6所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物的制备方法,其特征在于,步骤(2)中结构通式(III)的化合物与结构通式(IV)的化合物反应的摩尔比为1:1。8、一种如权利要求15任一项所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物或其药用盐在制备治疗肿瘤药物中的应用。9、一种如权利要求15任一项所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物或其药用盐在制备抗微生物感染药物中的应用。全文摘要本发明公开了一种以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物及其制备方法和应用,所述的以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物为具有如下结构通式(I)的化合物式(1)中,R<sub>1</sub>和R<sub>1</sub>′独立地选自H、(C<sub>1</sub>-C<sub>10</sub>)烷基、(C<sub>3</sub>-C<sub>10</sub>)环烷基、(C<sub>1</sub>-C<sub>10</sub>)卤代烷基、取代的芳香烃基或取代的杂环芳香烃基;R<sub>2</sub>和R<sub>2</sub>′独立地选自H、(C<sub>1</sub>-C<sub>7</sub>)烷基、(C<sub>3</sub>-C<sub>7</sub>)环烷基、取代的芳香烃基、取代的杂环芳香烃基、烃类酰基或磺酰基;R<sub>3</sub>和R<sub>3</sub>′独立地选自H、(C<sub>1</sub>-C<sub>5</sub>)烷基、(C<sub>3</sub>-C<sub>5</sub>)环烷基、取代的芳香烃基或取代的杂环芳香烃基;X和Y独立地选自CH、N或与卤素、烃基、烃氧基、烃硫基、氨基、取代氨基、取代的芳香烃基或取代的杂环芳香烃基相连的碳原子。本发明以噁二唑为连接链的C3/C3氟喹诺酮二聚体衍生物可用于制备治疗肿瘤及抗微生物感染疾病的药物。文档编号C07D413/00GK101643471SQ20091006591公开日2010年2月10日申请日期2009年8月24日优先权日2009年8月24日发明者磊伊,侯莉莉,孙茂峰,张俊珂,勇杨,胡国强,谢松强申请人:河南大学

本文地址:https://www.jishuxx.com/zhuanli/20240619/2623.html

版权声明:本文内容由互联网用户自发贡献,该文观点仅代表作者本人。本站仅提供信息存储空间服务,不拥有所有权,不承担相关法律责任。如发现本站有涉嫌抄袭侵权/违法违规的内容, 请发送邮件至 YYfuon@163.com 举报,一经查实,本站将立刻删除。